var title_f1_27_1456="Mobilization of the left colon";
var content_f1_27_1456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobilization of the left colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the mobilization of the left colon by retracting the sigmoid and left colon medially. The line of Toldt is incised and the colon released from the peritoneal attachments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1456=[""].join("\n");
var outline_f1_27_1456=null;
var title_f1_27_1457="Optic nerve coloboma";
var content_f1_27_1457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic nerve coloboma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: Optic nerve coloboma. Note the well-demarcated inferior excavation with thinning of the inferior neuroretinal rim and preservation of the superior rim. Right: The normal fellow optic disc.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1457=[""].join("\n");
var outline_f1_27_1457=null;
var title_f1_27_1458="Patient information: Pheochromocytoma (The Basics)";
var content_f1_27_1458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17223\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\">",
"         Endocrine glands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/34/5666\">",
"         Patient information: Tachycardia (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pheochromocytoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pheochromocytoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11178658\">",
"      <span class=\"h1\">",
"       What is a pheochromocytoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pheochromocytoma is a rare type of tumor. It usually happens in or near the adrenal glands. These are small organs that sit on top of each kidney (",
"      <a class=\"graphic graphic_figure graphicRef67279 \" href=\"UTD.htm?26/50/27424\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      A pheochromocytoma makes too much of a hormone called &ldquo;adrenaline.&rdquo; This is the &ldquo;fight or flight&rdquo; hormone. Having too much of this hormone can cause attacks of very high blood pressure, fast heart rate, sweating, and headaches. Some people call these attacks &ldquo;spells.&rdquo;",
"     </p>",
"     <p>",
"      Usually, pheochromocytomas happen in adults. But they sometimes happen in children and they can run in families. People with rare diseases such as endocrine neoplasia (also called &ldquo;MEN&rdquo;) and von Hippel-Lindau disease are more likely to have pheochromocytomas.",
"     </p>",
"     <p>",
"      They are more likely to be cancerous in children than in adults. But a pheochromocytoma can be serious even if there is no cancer. The &ldquo;fight or flight&rdquo; hormone it makes can damage the heart and even cause death. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11178672\">",
"      <span class=\"h1\">",
"       What are the symptoms of a pheochromocytoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms are different for each person. Adults and children can have different symptoms.",
"     </p>",
"     <p>",
"      Common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headaches &ndash; These can be mild or severe, and last a long or short time",
"       </li>",
"       <li>",
"        Sweating",
"       </li>",
"       <li>",
"        Fast heartbeat, or feeling like the heart is beating very hard or skips beats",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        Shaking",
"       </li>",
"       <li>",
"        Looking pale",
"       </li>",
"       <li>",
"        Feeling short of breath, weak, or both &nbsp;",
"       </li>",
"       <li>",
"        Feeling fearful or anxious",
"       </li>",
"       <li>",
"        Belly pain or swelling. This is more likely in children.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with pheochromocytomas do not have any symptoms.",
"     </p>",
"     <p>",
"      Many people with pheochromocytomas have very high blood pressure that can be dangerous. Blood pressure can go up and down if a person changes position or for other reasons.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11178687\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you and do an exam. He or she will also do lab tests to measure the hormone levels in your body. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Before you have tests, tell the doctor or nurse about any medicines you take. This includes prescription and over-the-counter medicines. You might need to stop taking them before having tests. Some medicines change hormone levels, and this could make the test results wrong. &nbsp;",
"     </p>",
"     <p>",
"      If blood or urine tests show someone has a pheochromocytoma, doctors do tests to find it in the body. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        CT or MRI scans of the adrenal glands",
"       </li>",
"       <li>",
"        Other imaging tests, if the CT or MRI does not show a tumor in the adrenal glands.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11178704\">",
"      <span class=\"h1\">",
"       How is a pheochromocytoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pheochromocytoma is treated with surgery to remove it.",
"     </p>",
"     <p>",
"      Before surgery, doctors give medicine to get the blood pressure and heart rate under control. This helps prevent serious problems during surgery. Medicine is given for about 2 weeks before surgery.",
"     </p>",
"     <p>",
"      Pheochromoctyomas are usually not cancerous. But if a pheochromocytoma is cancerous, doctors take out as much of it as possible. They can also treat cancer with radiation, chemotherapy, or other treatments.",
"     </p>",
"     <p>",
"      Most people are cured with surgery. But a pheochromocytoma can also come back, even after surgery. Sometimes, pheochromocytomas that were not cancerous at first come back as cancer. After treatment, plan to get checkups as often as the doctor recommends. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11178719\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, the doctor can give medicine to help control symptoms from the pheochromocytoma. You might have surgery to remove it if you are less than 24 weeks pregnant.",
"     </p>",
"     <p>",
"      When your baby has grown enough to live outside your body, the doctor can do a C-section (surgery to get the baby out). He or she can remove the tumor at the same time. If you have a pheochromocytoma, having a C-section is safer than giving birth through your vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11178734\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=see_link\">",
"       Patient information: Tachycardia (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/27/1458?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17223 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-201.65.114.212-30F76E55B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1458=[""].join("\n");
var outline_f1_27_1458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11178658\">",
"      What is a pheochromocytoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11178672\">",
"      What are the symptoms of a pheochromocytoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11178687\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11178704\">",
"      How is a pheochromocytoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11178719\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11178734\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27424\">",
"      Endocrine glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=related_link\">",
"      Patient information: Tachycardia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_27_1459="Anaplasmosis peripheral smear";
var content_f1_27_1459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Morulae of anaplasmosis in circulating neutrophils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 51-year-old man with no significant past medical history presented with a five-day history of fever, malaise, and diffuse myalgias with no recollection of a tick bite. He was found to have thrombocytopenia, elevated transaminase levels, and renal insufficiency. Examination of the peripheral smear suggested the diagnosis of anaplasmosis. He was started on a course of doxycycline with eventual complete resolution of symptoms.",
"    <br>",
"     The peripheral smear (1000x, \"feather edge\") shows morulae of anaplasmosis in the patient's granulocytes. Photomicrographs B and C were taken from the extreme feather edge, and show exploded neutrophils containing well-delineated morulae.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Peripheral smear and patient information kindly provided by Dr. Eddy J Chen and Dr. German Pihan, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1459=[""].join("\n");
var outline_f1_27_1459=null;
var title_f1_27_1460="Acyclovir (topical): Drug information";
var content_f1_27_1460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acyclovir (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/60/40899?source=see_link\">",
"    see \"Acyclovir (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/51/9011?source=see_link\">",
"    see \"Acyclovir (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7908397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7908398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7908400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7908498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Genital HSV:",
"     </b>",
"     Topical: Immunocompromised: Ointment: Initial episode:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; ribbon of ointment for a 4&rdquo; square surface area every 3 hours (6 times/day) for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Herpes labialis (cold sores):",
"     </b>",
"     Topical: Apply 5 times/day for 4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mucocutaneous HSV:",
"     </b>",
"     Topical: Ointment: Non-life-threatening, immunocompromised:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     &rdquo; ribbon of ointment for a 4&rdquo; square surface area every 3 hours (6 times/day) for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7908495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/51/9011?source=see_link\">",
"      see \"Acyclovir (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Herpes labialis (cold sores):",
"     </b>",
"     Topical: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7912838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7908562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 5% (2 g, 5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 5% (15 g, 30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7912809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes cream",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7908548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Topical: Not for use in the eye. Apply using a finger cot or rubber glove to avoid transmission to other parts of the body or to other persons.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7908471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of herpes labialis (cold sores), mucocutaneous HSV in immunocompromised patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7908396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acyclovir may be confused with ganciclovir, Retrovir&reg;, valacyclovir",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zovirax&reg; may be confused with Doribax&reg;, Valtrex&reg;, Zithromax&reg;, Zostrix&reg;, Zyloprim&reg;, Zyvox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Opthavir [Mexico] may be confused with Optivar brand name for azelastine [U.S.]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7908485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Mild pain, burning, or stinging (ointment 30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Pruritus (ointment 4%), itching",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7908472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7908473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Genital herpes: Appropriate use: Physical contact should be avoided when lesions are present; transmission may also occur in the absence of symptoms. Treatment should begin with the first signs or symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Herpes labialis: Appropriate use: For external use only to the lips and face; do not apply to eye or inside the mouth or nose. Treatment should begin with the first signs or symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: Use with caution in immunocompromised patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7912821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7912816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7912817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. When administered orally, acyclovir crosses the placenta. Refer to the Acyclovir, Systemic monograph for details. The amount of acyclovir available systemically following topical application of the cream or ointment is significantly less in comparison to oral doses.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7912820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, acyclovir enters breast milk. Refer to the Acyclovir, Systemic monograph for details. The amount of acyclovir available systemically following topical application of the cream or ointment is significantly less in comparison to oral doses. Nursing mothers with herpetic lesions near or on the breast should avoid breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7913156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Zovirax External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (5 g): $395.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Zovirax External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30 g): $807.28",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A.C.V. (TH);",
"     </li>",
"     <li>",
"      Acic (EE);",
"     </li>",
"     <li>",
"      Acic Creme (DE);",
"     </li>",
"     <li>",
"      Aciclidan (DK);",
"     </li>",
"     <li>",
"      Aciclomed (BE);",
"     </li>",
"     <li>",
"      Aciclor (VE);",
"     </li>",
"     <li>",
"      Aciclosina (PT);",
"     </li>",
"     <li>",
"      Acifar (ID);",
"     </li>",
"     <li>",
"      Aciherpin (PH);",
"     </li>",
"     <li>",
"      Acilax Cream (HK);",
"     </li>",
"     <li>",
"      Acivir (CH, IL, IN);",
"     </li>",
"     <li>",
"      Acivir Cold Sore Cream (AU);",
"     </li>",
"     <li>",
"      Acivirex (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Activir (FR);",
"     </li>",
"     <li>",
"      Acyvir (EC);",
"     </li>",
"     <li>",
"      Anti (SE);",
"     </li>",
"     <li>",
"      Antix (NO);",
"     </li>",
"     <li>",
"      Avir (VE);",
"     </li>",
"     <li>",
"      Avorax (SG);",
"     </li>",
"     <li>",
"      Cicloferon (CR, DO, GT, PA, SV);",
"     </li>",
"     <li>",
"      Cicloviral (CO);",
"     </li>",
"     <li>",
"      Clinovir (ID, TH);",
"     </li>",
"     <li>",
"      Clovir (TW);",
"     </li>",
"     <li>",
"      Covelay (PH);",
"     </li>",
"     <li>",
"      Covir Cream (TH);",
"     </li>",
"     <li>",
"      Cycloherp (HK);",
"     </li>",
"     <li>",
"      Cyclomed (IL);",
"     </li>",
"     <li>",
"      Cyclostad (PH);",
"     </li>",
"     <li>",
"      Cyclovax (HK);",
"     </li>",
"     <li>",
"      Cyclovir (IN);",
"     </li>",
"     <li>",
"      Danovir (ID);",
"     </li>",
"     <li>",
"      Declovir (HK);",
"     </li>",
"     <li>",
"      Deherp (TW);",
"     </li>",
"     <li>",
"      Dravyr (SG);",
"     </li>",
"     <li>",
"      Ecuvir (EC);",
"     </li>",
"     <li>",
"      Entir (TH);",
"     </li>",
"     <li>",
"      Eurovir (PY);",
"     </li>",
"     <li>",
"      Expit (UY);",
"     </li>",
"     <li>",
"      Ezopen Creme (BR);",
"     </li>",
"     <li>",
"      Herpesin (CZ);",
"     </li>",
"     <li>",
"      Herpevir (FR);",
"     </li>",
"     <li>",
"      Herpex (IN);",
"     </li>",
"     <li>",
"      Lisovyr Cream (AR);",
"     </li>",
"     <li>",
"      Lisovyr Crema (CN);",
"     </li>",
"     <li>",
"      Lovire (ZA);",
"     </li>",
"     <li>",
"      Marvir (TH);",
"     </li>",
"     <li>",
"      Medovir (MY);",
"     </li>",
"     <li>",
"      Oppvir (TW);",
"     </li>",
"     <li>",
"      Poviral (AR);",
"     </li>",
"     <li>",
"      Qualiclovir (HK);",
"     </li>",
"     <li>",
"      Remex (FR);",
"     </li>",
"     <li>",
"      Vicorax (TW);",
"     </li>",
"     <li>",
"      Viratop (BE);",
"     </li>",
"     <li>",
"      Virex (CO);",
"     </li>",
"     <li>",
"      Virless (SG);",
"     </li>",
"     <li>",
"      Virogon (TH);",
"     </li>",
"     <li>",
"      Virzin (DE);",
"     </li>",
"     <li>",
"      Vivir (KP);",
"     </li>",
"     <li>",
"      Zeven (MY);",
"     </li>",
"     <li>",
"      Zevin (TH);",
"     </li>",
"     <li>",
"      Zoral (HK, MY, SG);",
"     </li>",
"     <li>",
"      Zorax (SG);",
"     </li>",
"     <li>",
"      Zovir (DK);",
"     </li>",
"     <li>",
"      Zovirax (AR, AU, BB, BE, BM, BR, BS, CH, CL, CN, CZ, EC, EE, FI, FR, GB, GY, HK, ID, IE, IL, JM, KP, MY, NL, NO, NZ, PE, PR, PT, PY, SE, TH, TT, TW, UY, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7908491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9770059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Plasma concentrations following topical application of the cream were below the limit of detection in 5/6 male volunteers (&lt;0.01&mu;M) and 0.014 &mu;M in one subject. Following application of the ointment to patients with varicella-zoster infection, acyclovir plasma concentrations were &lt;0.01-0.28 mcg/mL in patients with normal renal function and &lt;0.01-0.78 mcg/mL in a patient with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (0.04% of the daily dose following topical application of the cream; &lt;0.02% to 9.4% of the daily dose following topical application of the ointment)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8649 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1460=[""].join("\n");
var outline_f1_27_1460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908398\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908400\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908498\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908495\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912838\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908562\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908548\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908471\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908396\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908485\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908472\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908473\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298683\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912821\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912816\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912817\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912820\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913156\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961952\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908491\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770059\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"UTD.htm?17/42/18081?source=related_link\">",
"      Acyclovir (ophthalmic): International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/40/37512?source=related_link\">",
"      Acyclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/48/38660?source=related_link\">",
"      Acyclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/37/2649?source=related_link\">",
"      Acyclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/60/40899?source=related_link\">",
"      Acyclovir (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/51/9011?source=related_link\">",
"      Acyclovir (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_27_1461="Maternal and economic benefits of breastfeeding";
var content_f1_27_1461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maternal and economic benefits of breastfeeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Richard J Schanler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1461/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/27/1461/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that breastfeeding provides direct and potentially long-term benefits to the infant. In addition, breastfeeding is associated with benefits to the mother during lactation and long-term. There are also significant economic benefits for the family and society.",
"   </p>",
"   <p>",
"    The maternal and economic benefits of breastfeeding will be reviewed here. The benefits of breastfeeding for the infant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MATERNAL BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with infants, breastfeeding provides direct clinical benefits to mothers during lactation and long-term benefits beyond the breastfeeding period. In a report for the Agency for Healthcare Research and Quality, review of the literature demonstrated benefits of breastfeeding for both the mother and infant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits to mothers while breastfeeding include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acceleration of recovery from childbirth by oxytocin's action on uterine involution [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Oxytocin secretion is stimulated by breastfeeding.",
"     </li>",
"     <li>",
"      Reduction of maternal response to stress [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. It has been suggested that the neuroendocrine peptides, oxytocin and prolactin, are important components of the stress axis and have a positive impact on social behaviors including maternal-infant bonding [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/4\">",
"       4",
"      </a>",
"      ]. Lower rates of maternal neglect and child abuse have also been observed in breastfeeding infants compared to those who are formula fed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weight loss after pregnancy may be enhanced by breastfeeding [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolongation of postpartum anovulation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Although breastfeeding prolongs anovulation, it should not be considered an entirely reliable means of contraception.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term benefits",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding has been shown to reduce the risk of both breast and ovarian cancer. These associations are discussed elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092327#H6092327\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Breastfeeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link&amp;anchor=H1067591512#H1067591512\">",
"     \"Factors that modify breast cancer risk in women\", section on 'Absence of breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether breastfeeding decreases the risk of osteoporosis. In premenopausal women, higher peak bone mass is associated with lower risk of postmenopausal osteoporosis. Indirect support for lactation's potential protective role against osteoporosis is provided by several studies that have shown lactation compared to nonlactation increased bone mineral density (BMD), [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. One study, utilizing data from the National Health and Nutrition Examination Survey III (1988 to 1994), found that women who breastfed as adolescents had a BMD (measured by dual energy x-ray absorptiometry) that was 5 to 10 percent greater than those who did not breastfeed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/12\">",
"     12",
"    </a>",
"    ]. However, others have not found an association between breastfeeding and subsequent higher BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/13\">",
"     13",
"    </a>",
"    ]. It remains unclear whether lactation reduces the risk of osteoporosis and further studies are required.",
"   </p>",
"   <p>",
"    In one study, a history of lactation was shown to confer a protective effect against osteoporosis and bone fracture in women over 65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/14\">",
"     14",
"    </a>",
"    ]. However, another study with a similar study population failed to replicate this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cumulative lactation appears to decrease the risk of cardiovascular disease (CVD) and obesity as demonstrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the Women's Health Initiative of postmenopausal women, multivariate-adjusted analysis showed women who breastfed were less likely than those who never breastfed to have hypertension, diabetes, hyperlipidemia, and CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/16\">",
"       16",
"      </a>",
"      ]. Longer accumulation of breastfeeding led to lower rates of CVD and related risk factors. Over the 7.9 years of the study, women with a single live birth who breast-fed for 7 to 12 months were less likely to develop CVD compared to those who had never breast-fed (Hazard ratio 0.72, 95% CI 0.53 TO 0.97).",
"     </li>",
"     <li>",
"      In a report from the Nurse's Health Study, multivariate-adjusted analysis demonstrated women who had breastfed for a lifetime total of two years of more compared to women who had never breastfed had a lower risk of coronary heart disease (hazard ratio of 0.77, 95% CI 0.62 to 0.94) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from the Study of Women Across the Nation-Heart Study, women who breastfed all of their children for at least three months compared to those who never breastfed were less likely to have vascular changes associated with CVD (ie, carotid artery and aortic calcification) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 607 mothers from the Women and Infants Study of Healthy Hearts, multivariate analysis adjusting for confound factors showed that women who never breastfed, compared with those who did, were more likely to have vascular findings associated with a greater risk of CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ECONOMIC BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The economic advantages of breastfeeding can be tangibly calculated at the family and national levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Familial benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obvious advantage for a family is in the savings accrued by not buying formula, a figure conservatively estimated to be about $1000 per year. In addition, the decreased risk of illness in breast-fed infants results in fewer outpatient visits and hospitalizations. For the individual family, this translates to decreased out-of-pocket expenditures for co-payments for visits and medications, and decreased work absences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Societal benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The societal benefits of exclusive breastfeeding for six months include an enormous economic savings and a reduction in infant mortality.",
"   </p>",
"   <p>",
"    Savings come from a combined reduction in household expenditure on formula, as well as reductions in expenditures for health care [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, the annual costs of",
"    <strong>",
"     not",
"    </strong>",
"    breastfeeding were computed for a health maintenance organization population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared with never breastfeeding, those infants who breastfed for &ge;three months had fewer medical office visits, medications, procedures, and hospitalizations. This amounted to a saving of $331 per single infant in short-term acute medical care costs only. In the managed care setting, full breastfeeding is estimated to reduce by 20 percent the total medical expenses compared with never breastfeeding. Not included in these cost estimates are the fewer work absences of families who are breastfeeding their infants.",
"   </p>",
"   <p>",
"    In another analysis using the above methodology, the estimated national cost savings would be 13 billion dollars for the year 2007 if 80 to 90 percent of families in the United States complied with the recommendation to exclusively breastfeed for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1461/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, an excess of 911 deaths (mostly infants) would be avoided.",
"   </p>",
"   <p>",
"    Furthermore, the cost savings from long-term benefits of breastfeeding, such as reducing the incidence of chronic diseases in childhood and reducing the incidence of breast cancer in women, would be substantial. Thus, the economic incentives for a society to breastfeed are strong and should be promoted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=see_link\">",
"       \"Patient information: Breast pumps (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       \"Patient information: Breast pumps (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2128423\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding is associated with maternal benefits during lactation and long-term, and significant economic benefits for both society and the family.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal benefits of breastfeeding during lactation include accelerated recovery from childbirth, reduced response to stress, enhanced weight loss, and prolongation of anovulation, although breastfeeding is not a reliable means of contraception. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term maternal benefits of breastfeeding include reduction in the risk of both breast and ovarian cancer, and a possible reduction in the risk of cardiovascular disease and obesity. It remains uncertain whether breastfeeding decreases the risk of osteoporosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Long-term benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breastfeeding decreases out-of-pocket expenditures because it reduces the expense of buying formula. In addition, because of the decreased risk of illness in breast-fed infants, there is a reduction in copayments for outpatient visits, hospitalizations, and medications, and a decrease in parental work absences. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Familial benefit'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H9#H9\">",
"       \"Infant benefits of breastfeeding\", section on 'Prevention of illnesses while breastfeeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Societal benefits of breastfeeding include economic savings (reduction in expenditure for formula and health care) and a reduction in infant mortality. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Societal benefit'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"       \"Infant benefits of breastfeeding\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.ahrq.gov/downloads/pub/evidence/pdf/brfout/brfout.pdf (Accessed on June 05, 2008).",
"    </li>",
"    <li>",
"     Riordan J. Anatomy and psychophysiology of lactation. In: Breastfeeding and Human Lactation, Riordan J, Auerbach KG (Eds), Jones and Bartlett, Boston 1993. p.83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/3\">",
"      Chua S, Arulkumaran S, Lim I, et al. Influence of breastfeeding and nipple stimulation on postpartum uterine activity. Br J Obstet Gynaecol 1994; 101:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/4\">",
"      Carter CS, Altemus M. Integrative functions of lactational hormones in social behavior and stress management. Ann N Y Acad Sci 1997; 807:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/5\">",
"      Mezzacappa ES, Kelsey RM, Katkin ES. Breast feeding, bottle feeding, and maternal autonomic responses to stress. J Psychosom Res 2005; 58:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/6\">",
"      Strathearn L, Mamun AA, Najman JM, O'Callaghan MJ. Does breastfeeding protect against substantiated child abuse and neglect? A 15-year cohort study. Pediatrics 2009; 123:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/7\">",
"      Dewey KG, Heinig MJ, Nommsen LA. Maternal weight-loss patterns during prolonged lactation. Am J Clin Nutr 1993; 58:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/8\">",
"      Wang IY, Fraser IS. Reproductive function and contraception in the postpartum period. Obstet Gynecol Surv 1994; 49:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/9\">",
"      Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993; 169:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/10\">",
"      Paton LM, Alexander JL, Nowson CA, et al. Pregnancy and lactation have no long-term deleterious effect on measures of bone mineral in healthy women: a twin study. Am J Clin Nutr 2003; 77:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/11\">",
"      Melton LJ 3rd, Bryant SC, Wahner HW, et al. Influence of breastfeeding and other reproductive factors on bone mass later in life. Osteoporos Int 1993; 3:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/12\">",
"      Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 2004; 158:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/13\">",
"      Grainge MJ, Coupland CA, Cliffe SJ, et al. Reproductive, menstrual and menopausal factors: which are associated with bone mineral density in early postmenopausal women? Osteoporos Int 2001; 12:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/14\">",
"      Cumming RG, Klineberg RJ. Breastfeeding and other reproductive factors and the risk of hip fractures in elderly women. Int J Epidemiol 1993; 22:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/15\">",
"      Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/16\">",
"      Schwarz EB, Ray RM, Stuebe AM, et al. Duration of lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol 2009; 113:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/17\">",
"      Stuebe AM, Michels KB, Willett WC, et al. Duration of lactation and incidence of myocardial infarction in middle to late adulthood. Am J Obstet Gynecol 2009; 200:138.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/18\">",
"      Schwarz EB, McClure CK, Tepper PG, et al. Lactation and maternal measures of subclinical cardiovascular disease. Obstet Gynecol 2010; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/19\">",
"      McClure CK, Catov JM, Ness RB, Schwarz EB. Lactation and maternal subclinical cardiovascular disease among premenopausal women. Am J Obstet Gynecol 2012; 207:46.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Weimer JP. Economic benefits of breastfeeding: a review and analysis. US Dept of Agriculture. Economic Research Service. Food Assistance and Nutrition Research Report. Washington, DC, 2001, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/21\">",
"      Cattaneo A, Ronfani L, Burmaz T, et al. Infant feeding and cost of health care: a cohort study. Acta Paediatr 2006; 95:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/22\">",
"      Ball TM, Bennett DM. The economic impact of breastfeeding. Pediatr Clin North Am 2001; 48:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1461/abstract/23\">",
"      Bartick M, Reinhold A. The burden of suboptimal breastfeeding in the United States: a pediatric cost analysis. Pediatrics 2010; 125:e1048.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5022 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1461=[""].join("\n");
var outline_f1_27_1461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2128423\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MATERNAL BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ECONOMIC BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Familial benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Societal benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2128423\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=related_link\">",
"      Patient information: Breast pumps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_27_1462="Cholestyramine resin: Pediatric drug information";
var content_f1_27_1462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cholestyramine resin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"    see \"Cholestyramine resin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34917?source=see_link\">",
"    see \"Cholestyramine resin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prevalite&reg;;",
"     </li>",
"     <li>",
"      Questran&reg;;",
"     </li>",
"     <li>",
"      Questran&reg; Light",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Novo-Cholamine;",
"     </li>",
"     <li>",
"      Novo-Cholamine Light;",
"     </li>",
"     <li>",
"      Olestyr;",
"     </li>",
"     <li>",
"      PMS-Cholestyramine;",
"     </li>",
"     <li>",
"      Questran&reg;;",
"     </li>",
"     <li>",
"      Questran&reg; Light Sugar Free;",
"     </li>",
"     <li>",
"      ZYM-Cholestyramine-Light;",
"     </li>",
"     <li>",
"      ZYM-Cholestyramine-Regular",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent, Bile Acid Sequestrant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"      see \"Cholestyramine resin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (dosages are expressed in terms of anhydrous resin):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 240 mg/kg/day in 3 divided doses; need to titrate dose depending on indication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypercholesterolemia (",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;8 g/day may not provide additional significant cholesterol-lowering effects, but may increase adverse effects): Some centers use the following doses (Sprecher, 1996):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;10 years: Initial: 2 g/day; titrate dose based on efficacy and tolerance; range: 1-4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;10 years and Adolescents: Initial: 2 g/day; titrate dose based on efficacy and tolerance, up to 8 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Lipid-lowering effects are better if dose is administered as a single daily dose with the evening meal (single daily morning doses are less effective); if patients cannot tolerate once daily dosing, the dose/day may be divided into 2 doses and administered with the morning and evening meals; may also be administered in 3 divided doses/day (Daniels, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 3-4 g 3-4 times/day to a maximum of 16-32 g/day in 2-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: Cholestyramine resin 4 g/5 g of powder (210 g); Cholestyramine resin 4 g/5.7 g of powder (239.4 g); Cholestyramine resin 4 g/9 g of powder (378 g); Cholestyramine resin 4 g/5 g packet (60s); Cholestyramine resin 4 g/5.7 g packet (60s); Cholestyramine resin 4 g/9 g packet (60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevalite&reg;: Cholestyramine resin 4 g/5.5 g of powder (231 g); Cholestyramine resin 4 g/5.5 g packet (42s, 60s) [contains phenylalanine 14.1 mg/5.5 g; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Questran&reg;: Cholestyramine resin 4 g/9 g of powder (378 g); Cholestyramine resin 4 g/9 g packet (60s) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Questran&reg; Light: Cholestyramine resin 4 g/5 g of powder (210 g); Cholestyramine resin 4 g/5 g packet (60s) [contains phenylalanine 14 mg/5 g; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer at mealtime; do not administer the powder in its dry form; just prior to administration, mix with 2-6 ounces of water, noncarbonated liquid, or applesauce; to minimize binding of concomitant medications, administer other drugs including vitamins or mineral supplements at least 1 hour before or at least 4-6 hours after cholestyramine",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in the management of primary hypercholesterolemia (FDA approved in adults) (see Additional Information for recommendations on initiating hypercholesterolemia pharmacologic treatment in children &ge;8 years); pruritus associated with elevated levels of bile acids (FDA approved in adults); diarrhea associated with excess fecal bile acids; pseudomembraneous colitis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F150895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, drowsiness, eructation, fatigue, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, rash, skin irritation, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperchloremic acidosis (children), libido increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, biliary colic, black stools, constipation, dental bleeding, dental caries, dental erosion, diarrhea, diverticulitis, duodenal ulcer bleeding, dysphagia, eructation, flatulence, gallbladder calcification, GI hemorrhage, intestinal obstruction (rare), hemorrhoidal bleeding, nausea, pancreatitis, perianal irritation, rectal bleeding, rectal pain, steatorrhea, taste disturbance, tongue irritation, tooth discoloration, ulcer, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hypothrombinemia, liver function abnormalities, prothrombin time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis, backache, joint/muscle/nerve pain, osteoporosis, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Night blindness (rare), uveitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis, dysuria, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hiccups, swollen glands",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cholestyramine or any component; avoid using in complete biliary obstruction or biliary atresia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with constipation or recent abdominal surgery; may produce or exacerbate constipation problems; initiate therapy at a reduced dose in patients with a history of constipation; hemorrhoids may be worsened. Some products (eg, Prevalite&reg; and Questran&reg; Light) contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Cholestyramine Resin may decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Bile Acid Sequestrants may decrease the absorption of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens).  Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins).  Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: Bile Acid Sequestrants may decrease the absorption of Fibric Acid Derivatives.  Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: Cholestyramine Resin may decrease the serum concentration of Fluvastatin.  Management: Administer fluvastatin at least 1 hour or greater (particularly with extended-release form) before, or at least 4 hours after cholestyramine to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: Cholestyramine Resin may decrease the serum concentration of Methylfolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Cholestyramine Resin may decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Cholestyramine Resin may decrease the serum concentration of PHENobarbital.  Management: Administer phenobarbital at least 1 hour before or 4-6 hours after administration of cholestyramine in order to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bile Acid Sequestrants may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholestyramine (especially high doses or long-term therapy) may decrease the absorption of fat-soluble vitamins (vitamins A, D, E, and K), folic acid, calcium, iron, zinc, and magnesium; deficiencies may occur including hypoprothrombinemia and increased bleeding from vitamin K deficiency; supplementation of vitamins A, D, E, and K, folic acid, and iron may be required with high-dose, long-term therapy (administer vitamins or mineral supplements at least 1 hour before or at least 4-6 hours after cholestyramine)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F150846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F150859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholestyramine is not absorbed systemically, but may interfere with vitamin absorption; therefore, regular prenatal supplementation may not be adequate. There are no studies in pregnant women; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum cholesterol, serum triglycerides; with prolonged use, prothrombin time, liver enzymes, CBC, electrolytes; number of stools/day",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Forms a nonabsorbable complex with bile acids in the intestine, releasing chloride ions in the process; inhibits enterohepatic reuptake of intestinal bile salts and thereby increases the fecal loss of bile salt-bound low density lipoprotein cholesterol",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Maximum effect on serum cholesterol levels: Within 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Forms an insoluble complex with bile acids which is excreted in feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/27/1462/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, personal communication, May 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, O'Neill MB, Cullen-Dean G, et al, &ldquo;Acceptability and Compliance With Two Forms of Cholestyramine in the Treatment of Hypercholesterolemia in Children: A Randomized, Crossover Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1997, 130(2):266-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/27/1462/abstract-text/9042130/pubmed\" id=\"9042130\" target=\"_blank\">",
"        9042130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/27/1462/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sprecher DL and Daniels SR, &ldquo;Rational Approach to Pharmacologic Reduction of Cholesterol Levels in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(1):4-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/27/1462/abstract-text/8757557/pubmed\" id=\"8757557\" target=\"_blank\">",
"        8757557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),\" May 2001. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cholesterol\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cholesterol",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tonstad S, Knudtzon J, Sivertsen M, et al, &ldquo;Efficacy and Safety of Cholestyramine Therapy in Peripubertal and Prepubertal Children With Familial Hypercholesterolemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(1):42-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/27/1462/abstract-text/8757561/pubmed\" id=\"8757561\" target=\"_blank\">",
"        8757561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13152 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1462=[""].join("\n");
var outline_f1_27_1462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150870\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150871\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051702\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051696\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150849\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051705\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051704\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150895\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051709\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051695\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299034\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150843\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051712\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150846\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150859\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051701\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051694\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051707\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051708\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13152|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=related_link\">",
"      Cholestyramine resin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/6/34917?source=related_link\">",
"      Cholestyramine resin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_27_1463="Anatomy of the kidney and ureter - male";
var content_f1_27_1463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Anatomy of the kidney and ureter - male",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure depicts the retroperitoneal relationship of the kidneys and ureters in the male. The anatomic location of the ureters make them particularly vulnerable to injury during pelvic operations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1463=[""].join("\n");
var outline_f1_27_1463=null;
var title_f1_27_1464="Lipoprotein glomerulopathy";
var content_f1_27_1464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipoprotein glomerulopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1464/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1464/contributors\">",
"     Takao Saito, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1464/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1464/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/27/1464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoprotein glomerulopathy (LPG) is a unique and rare disorder of renal lipidosis that was first reported in a Japanese patient in 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/1\">",
"     1",
"    </a>",
"    ]. It is characterized by lipoprotein thrombi in glomeruli, an abnormal plasma lipoprotein profile that resembles type III hyperlipoproteinemia, and a marked increase in serum apolipoprotein E (ApoE) concentrations. LPG was subsequently found to be due to mutations of the ApoE gene [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the clinical features of lipoprotein glomerulopathy is presented in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports of familial cases as well as recurrence in transplanted kidneys suggested that a systemically acting genetic factor may underlie LPG. It was also observed that the serum ApoE isoform was inconsistent with the ApoE genotype among affected individuals.",
"   </p>",
"   <p>",
"    These findings predicted that an uncharacterized variant(s) of the ApoE gene may underlie the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"     3",
"    </a>",
"    ]. This was subsequently confirmed as mutations in the ApoE gene have been found in all reported cases of LPG in which DNA sequencing has been performed. (",
"    <a class=\"graphic graphic_algorithm graphicRef59528 \" href=\"UTD.htm?26/52/27471\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ApoE variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;ApoE, an essential apolipoprotein, is a major constituent of various plasma lipoproteins. Plasma lipoprotein levels are determined in part by the binding activities of ApoE to the LDL receptor, LDL receptor-related protein, and VLDL receptor. ApoE is composed of 299 amino acids and has a relative molecular mass of 34kDa.",
"   </p>",
"   <p>",
"    A number of serum isoforms of ApoE have been described. They differ based upon their migration properties as determined by isoelectric focusing polyacrylamide gel electrophoresis (IEF). The most common serum ApoE isoform is apo E3.",
"   </p>",
"   <p>",
"    Observations in patients with type III hyperlipoproteinemia provided insight into the pathogenesis of LPG. Type III hyperlipoproteinemia is a multifactorial disorder that is characterized by the presence of two apo E2 alleles. It is also occasionally associated with renal lipidosis showing sclerosis and foam cells in the glomerulus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among affected individuals with LPG (which is directly associated with renal lipidosis), the serum ApoE isoform was noted to be inconsistent with the ApoE genotype. This suggested that an uncharacterized variant(s) of the ApoE gene may underlie the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"     3",
"    </a>",
"    ]. Subsequently, mutations of the ApoE gene have been described in all patients with LPG in whom DNA sequencing has been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ], except for the cases in one report from China [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases from the eastern part of Japan, DNA sequence analysis of the ApoE gene reveal a nucleotide substitution of G to C at codon 145 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"       3",
"      </a>",
"      ]. This missense mutation results in an amino acid substitution of the proline residue for arginine residue at position 145 of ApoE, and was termed ApoE Sendai (",
"      <a class=\"graphic graphic_figure graphicRef70954 \" href=\"UTD.htm?2/23/2421\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Another major mutation called ApoE Kyoto is found world-wide in various races, including Japanese, Chinese and Caucasian [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/10-15\">",
"       10-15",
"      </a>",
"      ]. This mutation changes the amino acid at position 25 of ApoE from arginine to cysteine. This position is not directly related to the central portion (position 136 to 158) of ApoE, which is involved in binding to the LDL receptor. However, the removal of arginine at 25 could break the tertiary structure of ApoE, as well as the change at 145 in ApoE Sendai [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several other ApoE variants have been found in LPG patients (",
"      <a class=\"graphic graphic_figure graphicRef70954 \" href=\"UTD.htm?2/23/2421\">",
"       figure 1",
"      </a>",
"      ). Some are missense mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/11,14,16-20\">",
"       11,14,16-20",
"      </a>",
"      ], while others are inframe deletions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/21-23\">",
"       21-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most mutations detected in patients with LPG are found in",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    around the LDL receptor binding domain (",
"    <a class=\"graphic graphic_figure graphicRef70954 \" href=\"UTD.htm?2/23/2421\">",
"     figure 1",
"    </a>",
"    ). In particular, the substitutions of proline, eg, ApoE Sendai [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"     3",
"    </a>",
"    ], ApoE Chicago [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/24\">",
"     24",
"    </a>",
"    ], ApoE Guangzhou [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/18\">",
"     18",
"    </a>",
"    ] and ApoE",
"    <span class=\"nowrap\">",
"     Osaka/Kurashiki",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], are important mutations, because they may produce severe structural changes in the middle of the alpha-helix, thereby altering the three-dimensional conformation of the protein [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"     3",
"    </a>",
"    ]. It is hypothesized that the abnormal lipoproteins aggregate and then deposit in the glomerular capillary walls",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    around the mesangium, with subsequent transformation into lipoprotein thrombi.",
"   </p>",
"   <p>",
"    In vitro studies and murine models of LPG support the view that ApoE variants are directly responsible for these glomerular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipoprotein glomerulopathy results after transduction of the ApoE Sendai variant into mice with genetic deletion of the wild type ApoE gene [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In vitro studies reveal that the ApoE Sendai variant lipoprotein has reduced affinity for the low-density lipoprotein (LDL) receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/29\">",
"       29",
"      </a>",
"      ]. This decreased binding ability is shared with the apo E2 allele found in patients with familial type III hyperlipoproteinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/30-32\">",
"       30-32",
"      </a>",
"      ], which is also sometimes associated with renal lipidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the evidence in favor of a causative role for ApoE variants in LPG, several observations suggest that additional factors are involved in the induction of LPG. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are healthy carriers of ApoE variants in families with LPG.",
"     </li>",
"     <li>",
"      LPG-like lesions do not develop in all ApoE-Sendai transfected mice.",
"     </li>",
"     <li>",
"      LPG-like lesions have been observed in mice with hyperlipidemia and genetic deletion of the ApoE genes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lesions are confined to the glomeruli of LPG, suggesting that unique intrinsic glomerular factors found in the affected host interact with ApoE variants.",
"     </li>",
"     <li>",
"      Cases of LPG sometimes occur in association with other glomerular diseases, eg, IgA nephropathy, membranous glomerulopathy, lupus nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2,8\">",
"       2,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dysfunction of Fc receptors (FcRs) may be one such non-apo E factor. FcRs mediate the uptake of immune complex- or CRP-binding LDL into macrophages, thereby inducing phagocytosis and atherosclerosis with foam cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In mice, Fc receptor dysfunction can be induced by eliminating the FcR gamma chain, which is required to allow the surface expression and signal transduction of the receptor. In Fc receptor gamma chain (FcR gamma) knockout mice, LPG-like lesions characterized by lipoprotein thrombi are found in glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/38\">",
"     38",
"    </a>",
"    ]. The lack of scavenger receptors induced by FcR dysfunction may suppress the uptake of lipids by macrophages and contribute to form lipoprotein thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the first published case in 1989, more than 70 cases of LPG have been reported worldwide. Most cases have been found in Japan and East Asian countries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ]. However, cases outside of Asia, such as the United States and Europe, have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/11,19,20,24,40-45\">",
"     11,19,20,24,40-45",
"    </a>",
"    ]. In the seven cases from the United States, four are of European ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/11,19,43\">",
"     11,19,43",
"    </a>",
"    ], two are of Asian ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/40,44\">",
"     40,44",
"    </a>",
"    ], and one is Mexican [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/24\">",
"     24",
"    </a>",
"    ]. Three Italian and two French cases are Caucasian [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/20,41,42\">",
"     20,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with LPG are asymptomatic. The average age is 32 years old, although the age at onset varies widely (ranging from 4 to 69 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ]). The male to female ratio is approximately 3:2.",
"   </p>",
"   <p>",
"    Affected patients usually come to medical attention after the detection of proteinuria on routine screening examination. Some patients present with symptoms and signs of the nephrotic syndrome.",
"   </p>",
"   <p>",
"    Inheritance of LPG appears to be autosomal dominant with variable penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;At presentation, all patients with LPG have proteinuria of variable severity, ranging from mild to severe. Most eventually develop nephrotic syndrome or nephrotic-range proteinuria. The average urinary protein excretion of reported patients at time of renal biopsy is 4.8 grams per day (range of 0.3 to 18",
"    <span class=\"nowrap\">",
"     grams/day).",
"    </span>",
"    Microscopic hematuria is usually not observed.",
"   </p>",
"   <p>",
"    Average creatinine clearance of patients is 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (range of 35 to 143",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) at the time of kidney biopsy. One-half of patients eventually develop end-stage renal disease at 1 to 27 years after disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ]. On average, this occurs within approximately 7.5 years from time of diagnosis, as calculated by Kaplan-Meier's method.",
"   </p>",
"   <p>",
"    In several cases, LPG has been associated with other glomerulopathies. These include IgA nephropathy, membranous nephropathy, and lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Non-renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic non-renal symptoms appear to be limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases, systemic manifestations, such as hypertension, atherosclerosis, cardiovascular change, and hepatic dysfunction, are mild. Among those with significant proteinuria, edema and decreased albumin levels are found.",
"     </li>",
"     <li>",
"      Clinical symptoms characteristic of lipidosis, such as corneal arcus, xanthoma and Achilles tendon thickening, are rarely observed.",
"     </li>",
"     <li>",
"      Cases with psoriasis vulgaris have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite comparatively high serum triglyceride levels, no cases of pancreatitis have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lipid and lipoprotein profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with LPG have hyperlipidemia with a predominance of triglycerides. When isolated by ultracentrifugation, high cholesterol levels are observed in very low-density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/47\">",
"     47",
"    </a>",
"    ]. Agarose gel electrophoresis for lipoprotein shows broad beta band. These findings are consistent with type III hyperlipoproteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the increased levels of triglycerides and cholesterol in plasma are frequently less pronounced than patients with familial type III hyperlipoproteinemia and are even occasionally within normal ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/21,50\">",
"     21,50",
"    </a>",
"    ]. Among reported patients, average plasma triglyceride and total cholesterol levels are 313",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range of 74 to 1019",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and 272",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range of 107 to 720",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high serum concentration of ApoE is another characteristic finding in LPG. The average plasma ApoE level is 17.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range of 3.9 to 71.0",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    which is approximately twofold higher than the upper normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the ApoE phenotype determined by isoelectric focusing polyacrylamide gel electrophoresis (IEF) shows heterozygosity for the E2 allele",
"    <span class=\"nowrap\">",
"     (E2/3",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     E2/4)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/8\">",
"     8",
"    </a>",
"    ]; this differs from that of familial type III hyperlipoproteinemia, which is homozygous for E2. In some cases, however, the protein band by IEF is recognized at the position of E1 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] or between E2 and E3 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/12,42\">",
"     12,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the ApoE genotype routinely determined by restriction fragment length polymorphism analysis (RFLP) with restriction enzyme HhaI shows",
"    <span class=\"nowrap\">",
"     E3/3",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     E3/4,",
"    </span>",
"    which is inconsistent with the ApoE phenotype as determined by IEF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Histopathologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on renal biopsy include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Light microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light microscopic examination of renal biopsy material shows marked dilatation of the capillary lumen in the glomeruli by a pale-stained substance (",
"    <a class=\"graphic graphic_picture graphicRef65560 \" href=\"UTD.htm?15/25/15764\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/1\">",
"     1",
"    </a>",
"    ]. Foam cells, which are characteristic of lipidosis, are rarely seen in either the glomeruli or the interstitium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electron microscopy shows that the thrombus-like substances in the glomerular capillaries are composed of granules and vacuoles of various sizes forming concentric lamellate like a fingerprint (",
"    <a class=\"graphic graphic_picture graphicRef62285 \" href=\"UTD.htm?3/3/3128\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/8,51\">",
"     8,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Confirmation of lipoprotein deposits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using snap-frozen kidney sections, immunofluorescence studies reveal deposition of apoB and ApoE (",
"    <a class=\"graphic graphic_picture graphicRef74959 \" href=\"UTD.htm?28/41/29330\">",
"     picture 3",
"    </a>",
"    ), and Sudan or oil-red O staining reveals lipid droplets in the thrombus-like substances (",
"    <a class=\"graphic graphic_picture graphicRef68230 \" href=\"UTD.htm?26/19/26934\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;LPG should be suspected in the patient who presents with proteinuria and dyslipidemia with a predominance of triglycerides. Initial evaluation includes lipoprotein and ApoE tests and agarose gel electrophoresis. Findings consistent with LPG include increased plasma VLDL and IDL levels, a broad beta-band on agarose gel electrophoresis, and a high serum ApoE level.",
"   </p>",
"   <p>",
"    If this initial evaluation is consistent with LPG, we always obtain a renal biopsy and perform analysis of ApoE phenotype and genotype. DNA sequence analysis is useful for the confirmation of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical elements most consistent with LPG include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteinuria",
"     </li>",
"     <li>",
"      Type III hyperlipoproteinemia with high levels of VLDL and IDL plus increased ApoE concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. This is usually associated with a heterozygous ApoE phenotype,",
"      <span class=\"nowrap\">",
"       E2/3",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       E2/4,",
"      </span>",
"      by immunoelectrophoresis but sometimes with an uncommon type, eg,",
"      <span class=\"nowrap\">",
"       E1/3",
"      </span>",
"      or others.",
"     </li>",
"     <li>",
"      Renal biopsy showing, on light microscopy, dilatation of glomerular capillary lumina with pale-stained substances and, on electron microscopy, stone- or sand-like granules occupying the capillary lumina.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To establish the diagnosis, DNA sequence analysis of ApoE should be conducted, if possible. ApoE variants have been detected in all LPG patients in whom DNA sequence was determined. At present, DNA sequence analysis of ApoE can be assayed in various commercial laboratories using blood samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of primary kidney diseases also present with significant proteinuria and renal dysfunction. Although analysis of lipoproteins and apolipoproteins may distinguish LPG from these diseases clinically, the diagnosis is definitively obtained by renal biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LPG is associated with segmental sclerosis of the glomerulus and mesangial interposition, findings also observed in focal segmental glomerulosclerosis and membranoproliferative glomerulonephritis, respectively. These disorders can be distinguished from LPG after DNA sequencing.",
"   </p>",
"   <p>",
"    In several reports, familial type III hyperlipoproteinemia due to ApoE2 homozygosity has been associated with renal lesions and lipoprotein thrombi that resemble those of LPG [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/4-6,52,53\">",
"     4-6,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective therapeutic regimen has been established for LPG. There have also been no controlled studies examining different therapeutic approaches, and none are likely to be conducted due to the rarity of the condition. Only case reports have been published concerning the efficacy of various agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Specific therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-lowering therapy consisting of different agents, either administered alone or in combination, have been examined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some case reports, intensive therapy using lipid-lowering agents including fibrates resulted in clinical remission with histological resolution [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/17,54-56\">",
"       17,54-56",
"      </a>",
"      ]. These cases reported reductions in serum cholesterol, triglycerides and ApoE levels and complete disappearance of lipoprotein thrombi in serial renal biopsies.",
"     </li>",
"     <li>",
"      The effects of HMG-CoA reductase inhibitors (eg, statins) are controversial. Statins do not seem to lower urinary protein excretion, even in those with remission of dyslipidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2,8\">",
"       2,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of plasmapheresis or LDL apheresis are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/8\">",
"     8",
"    </a>",
"    ], but beneficial treatment with staphylococcal protein A immunoadsorption was reported as a pilot study from China [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The administration of corticosteroids, immunosuppressant agents,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anticoagulants are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the absence of published evidence, we suggest the use of lipid lowering therapy. Our initial regimen consists of the administration of lipid-lowering agents, including a fibrate (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    ). We subsequently monitor serum lipid levels and serum creatinine concentrations as well as urinary protein excretion. We aim for normalization of lipid levels, reduction of urinary protein excretion, and stabilization of the serum creatinine concentration.",
"   </p>",
"   <p>",
"    If initial therapy is ineffective in sufficiently lowering proteinuria to goal levels by six months, we add angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB). (See next section).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Non-specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that angiotensin converting enzyme (ACE) inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers (ARB) are effective in LPG. However, based upon their effectiveness in other forms of proteinuric chronic kidney disease, we recommend the administration of ACE inhibitors or ARBs both for blood pressure control and to slow progression of the renal disease among those with persistent proteinuria (which is defined as inadequate lowering of proteinuria to goal levels by six months from initiation of specific therapy).",
"   </p>",
"   <p>",
"    The treatment goals with angiotensin inhibition are the same as those in other forms of proteinuric chronic kidney disease as described in the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a minimum reduction in protein excretion of at least 60 percent from baseline values, with goal protein excretion being less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Given simplicity and cost considerations, we initiate therapy with a single agent (either an ACE inhibitor or an ARB).",
"     </li>",
"     <li>",
"      The goal blood pressure is less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg, but even lower blood pressures may be beneficial in patients with persistent protein excretion above 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This recommendation is similar to that in other forms of proteinuric chronic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, four kidney transplants have been performed, and LPG has recurred in all transplanted allografts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/13,42,50,59\">",
"     13,42,50,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In one case report, kidney function was lost within one year [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum creatinine levels reached approximately 2",
"      <span class=\"nowrap\">",
"       mg/dL(176.8",
"      </span>",
"      <span class=\"nowrap\">",
"       &micro;mol/liter)",
"      </span>",
"      within four years in two cases [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/13,42\">",
"       13,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The last case revealed histologic recurrence one year after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1464/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no special selection between hemodialysis and peritoneal dialysis. However, hemodialysis appears to ameliorate the dyslipidemia in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipoprotein glomerulopathy (LPG) is a rare and unique disorder of renal lipidosis. More than 70 cases of LPG have been reported worldwide, with most cases being found in Japan and East Asian countries. However, cases outside of Asia, such as the United States and Europe, have been identified. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LPG results from mutations in the ApoE gene, with most mutations detected being found in",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      around the low-density lipoprotein receptor binding domain. Although unproven, it is hypothesized that the abnormal lipoproteins aggregate and then deposit in the glomerular capillary walls",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      around the mesangium, with subsequent transformation into lipoprotein thrombi. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At presentation, most patients are asymptomatic and come to medical attention after the detection of proteinuria on routine screening examination. All patients with LPG have proteinuria of variable severity, ranging from mild to severe proteinuria. Most eventually develop nephrotic syndrome or nephrotic-range proteinuria. One-half of patients eventually develop end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients also have hyperlipidemia with a predominance of triglycerides. Findings with ultracentrifugation and agarose gel electrophoresis are consistent with type III hyperlipoproteinemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lipid and lipoprotein profiles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kidney biopsy reveals marked dilatation of the capillary lumen in the glomeruli by a pale-stained substance on light microscopy and, on electron microscopy, thrombus-like substances in the glomerular capillaries that are composed of granules and vacuoles of various sizes. These substances form concentric lamellate, like a fingerprint. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Histopathologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LPG is diagnosed in the patient with proteinuria, type III hyperlipoproteinemia with high levels of VLDL and IDL plus increased ApoE concentration, and characteristic findings on renal biopsy. The diagnosis should be confirmed, if possible, with DNA sequence analysis of the ApoE gene. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No effective therapeutic regimen has been established for LPG. We suggest the use of lipid lowering therapy including a fibrate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We subsequently monitor serum lipid levels and creatinine concentrations, as well as urinary protein excretion. We aim for normalization of lipid levels, reduction of urinary protein excretion, and stabilization of serum creatinine concentration. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Specific therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent proteinuria (&gt;500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      we recommend angiotensin inhibition with an ACE inhibitor or ARB (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We initiate monotherapy and target a minimum reduction in protein excretion of at least 60 percent from baseline values, with goal protein excretion being less than 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Non-specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/1\">",
"      Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 1989; 13:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/2\">",
"      Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/3\">",
"      Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145--&gt;proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997; 8:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/4\">",
"      Amatruda JM, Margolis S, Hutchins GM. Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli. Arch Pathol 1974; 98:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/5\">",
"      Suzaki K, Kobori S, Ueno S, et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis 1990; 80:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/6\">",
"      Ellis D, Orchard TJ, Lombardozzi S, et al. Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity. J Am Soc Nephrol 1995; 6:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/7\">",
"      Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy. Trends Cardiovasc Med 2002; 12:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/8\">",
"      Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron 1999; 83:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/9\">",
"      Chen S, Liu ZH, Zheng JM, et al. A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy. J Nephrol 2007; 20:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/10\">",
"      Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999; 56:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/11\">",
"      Rovin BH, Roncone D, McKinley A, et al. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med 2007; 357:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/12\">",
"      Murano T, Matsumura R, Misawa Y, et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg--&gt;Cys) from a patient with lipoprotein glomerulopathy. Metabolism 2002; 51:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/13\">",
"      Foster K, Matsunaga A, Matalon R, et al. A rare cause of posttransplantation nephrotic syndrome. Am J Kidney Dis 2005; 45:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/14\">",
"      Cheung CY, Chan AO, Chan YH, et al. A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. Hong Kong Med J 2009; 15:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/15\">",
"      Han J, Pan Y, Chen Y, et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract 2010; 114:c260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/16\">",
"      Hagiwara M, Yamagata K, Matsunaga T, et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/17\">",
"      Kinomura M, Sugiyama H, Saito T, et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/18\">",
"      Luo B, Huang F, Liu Q, et al. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol 2008; 28:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/19\">",
"      Bomback AS, Song H, D'Agati VD, et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Nephrol Dial Transplant 2010; 25:3442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/20\">",
"      Russi G, Furci L, Leonelli M, et al. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. J Med Case Rep 2009; 3:9311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/21\">",
"      Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999; 83:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/22\">",
"      Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999; 56:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/23\">",
"      Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol 2000; 14:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/24\">",
"      Sam R, Wu H, Yue L, et al. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 2006; 47:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/25\">",
"      Mitani A, Ishigami M, Watase K, et al. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/26\">",
"      Tokura T, Itano S, Kobayashi S, et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/27\">",
"      Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 2000; 275:31269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/28\">",
"      Ishimura A, Watanabe M, Nakashima H, et al. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Clin Exp Nephrol 2009; 13:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/29\">",
"      Hoffmann M, Scharnagl H, Panagiotou E, et al. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 2001; 12:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/30\">",
"      Janus ED, Grant S, Lintott CJ, Wardell MR. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis 1985; 57:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/31\">",
"      Innerarity TL, Hui DY, Bersot TP, Mahley RW. Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions. Adv Exp Med Biol 1986; 201:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/32\">",
"      Ghiselli G, Gregg RE, Zech LA, et al. Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet 1982; 2:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/33\">",
"      Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002; 82:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/34\">",
"      Langheinrich AC, Kampschulte M, Scheiter F, et al. Atherosclerosis, inflammation and lipoprotein glomerulopathy in kidneys of apoE-/-/LDL-/- double knockout mice. BMC Nephrol 2010; 11:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/35\">",
"      Kiener PA, Rankin BM, Davis PM, et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995; 15:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/36\">",
"      Huang Y, Jaffa A, Koskinen S, et al. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 1999; 19:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/37\">",
"      Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/38\">",
"      Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol 2002; 13:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/39\">",
"      Miyahara Y, Nishimura S, Watanabe M, et al. Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. Clin Exp Nephrol 2012; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/40\">",
"      Zhang P, Matalon R, Kaplan L, et al. Lipoprotein glomerulopathy: first report in a Chinese male. Am J Kidney Dis 1994; 24:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/41\">",
"      Meyrier A, Dairou F, Callard P, Mougenot B. Lipoprotein glomerulopathy: first case in a white European. Nephrol Dial Transplant 1995; 10:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/42\">",
"      Mourad G, Djamali A, Turc-Baron C, Cristol JP. Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Nephrol Dial Transplant 1998; 13:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/43\">",
"      Boumendjel R, Papari M, Gonzalez M. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Arch Pathol Lab Med 2010; 134:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/44\">",
"      Sethi S. Renal failure with intracapillary thrombi. Lipoprotein glomerulopathy. Kidney Int 2008; 73:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/45\">",
"      Pasquariello A, Pasquariello G, Innocenti M, et al. Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. J Nephrol 2011; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/46\">",
"      Chang CF, Lin CC, Chen JY, et al. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. Am J Kidney Dis 2003; 42:E18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/47\">",
"      Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991; 18:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/48\">",
"      Hazzard WR, Porte D Jr, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type 3 hyperlipoproteinemia). Metabolism 1972; 21:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/49\">",
"      Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med 1975; 82:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/50\">",
"      Saito T, Sato H, Oikawa S, et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/51\">",
"      Saito T, Oikawa S, Sato H, et al. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int Suppl 1999; 71:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/52\">",
"      Amenomori M, Haneda M, Morikawa J, et al. A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron 1994; 67:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/53\">",
"      Sakatsume M, Kadomura M, Sakata I, et al. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int 2001; 59:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/54\">",
"      Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis 2003; 41:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/55\">",
"      Arai T, Yamashita S, Yamane M, et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 2003; 169:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/56\">",
"      Matsunaga A, Furuyama M, Hashimoto T, et al. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol 2009; 13:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/57\">",
"      Xin Z, Zhihong L, Shijun L, et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: a pilot study. Nephrol Dial Transplant 2009; 24:864.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Guidelines.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1464/abstract/59\">",
"      Miyata T, Sugiyama S, Nangaku M, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol 1999; 10:1590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3088 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1464=[""].join("\n");
var outline_f1_27_1464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ApoE variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Non-renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lipid and lipoprotein profiles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Histopathologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Light microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Confirmation of lipoprotein deposits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Specific therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Non-specific therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3088|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/52/27471\" title=\"algorithm 1\">",
"      Pathogenesis of LPG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3088|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/23/2421\" title=\"figure 1\">",
"      ApoE mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3088|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/25/15764\" title=\"picture 1\">",
"      Light microscopy kid LPG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/3/3128\" title=\"picture 2\">",
"      Electron micro kid LPG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/41/29330\" title=\"picture 3\">",
"      IF for apoE kid LPG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/19/26934\" title=\"picture 4\">",
"      Oil redO stain kid LPG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_27_1465="Seborrheic keratosis hyperpigmented";
var content_f1_27_1465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54386%7EOBGYN%2F70317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54386%7EOBGYN%2F70317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperpigmented seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1465=[""].join("\n");
var outline_f1_27_1465=null;
var title_f1_27_1466="Placement of subclavian venous catheters";
var content_f1_27_1466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placement of subclavian venous catheters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Mark P Androes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Alan C Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1466/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/27/1466/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/27/1466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H86790388\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central catheters provide dependable intravenous access and enable hemodynamic monitoring and blood sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The subclavian veins are a common site for temporary central venous access, particularly for tunneled catheters and subcutaneous ports for chemotherapy, prolonged antibiotic therapy, and long-term fluid therapy or parenteral nutrition.",
"   </p>",
"   <p>",
"    Subclavian venous cannulation and catheter placement will be reviewed here. General considerations, complications of venous access, and issues related to other access sites are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86790395\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subclavian veins are reliable access points for temporary and permanent (eg, tunneled central catheters and subcutaneous ports) venous cannulation to support hemodynamic monitoring, fluid and medication administration, and parenteral nutrition (",
"    <a class=\"graphic graphic_table graphicRef71716 \" href=\"UTD.htm?1/53/1885\">",
"     table 1",
"    </a>",
"    ). The left subclavian access is particularly well suited for cardiac access, including placement of pulmonary artery catheters, transvenous pacer leads, and implantable defibrillators.",
"   </p>",
"   <p>",
"    Subclavian venous access may be preferred for subcutaneous port placement due to the short distance between the subclavian vein and chest wall. Thus, the catheter is less prone to kinking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86790402\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative contraindications to subclavian venous catheterization, in general, include coagulopathy, prior access, the presence of another device at the site, and altered local anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of central venous access\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subclavian access should be avoided, if possible, at sites with altered local anatomy (eg, previous clavicle fracture), prior access, or sites with an indwelling pacemaker or internal defibrillator because these are associated with a higher risk of failure, complication, and malposition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with significant unilateral lung disease, we prefer cannulation of the side ipsilateral to the compromised lung to avoid decompensation in the event of a procedure-related pneumothorax.",
"   </p>",
"   <p>",
"    Subclavian site should be avoided for large bore hemodialysis catheters due to risk of venous stenosis that limits outflow for future arteriovenous hemodialysis access [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link&amp;anchor=H79681682#H79681682\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Access site considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subclavian access site is not appropriate for the short, relatively stiff catheters used for acute hemodialysis or pheresis. These catheters do not have the flexibility needed to negotiate the curve from the brachiocephalic vein into the superior vena cava. Perforation of the central veins can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coagulopathy is a relative contraindication to central cannulation. However, there is little quality evidence to support this preference [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/4\">",
"     4",
"    </a>",
"    ]. Although significant bleeding is uncommon, the subclavian approach is generally avoided in patients who are anticoagulated or those who have a coagulopathy if an alternative access point is available. Bleeding from the subclavian vein or inadvertent subclavian artery puncture may go unrecognized and cannot be treated with direct pressure due to the deep location of these vessels beneath the clavicle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86790409\">",
"    <span class=\"h1\">",
"     SUBCLAVIAN VEIN ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clavicle is the primary surface landmark for subclavian cannulation (",
"    <a class=\"graphic graphic_picture graphicRef62106 \" href=\"UTD.htm?1/53/1877\">",
"     picture 1",
"    </a>",
"    ). Moving laterally from the suprasternal notch, the bulky sternal head takes an elongated S-shape (a double curve in the horizontal plane); the medial two-thirds are convex anteriorly, and the lateral third is concave anteriorly. The anterior convexity at the junction of the medial and middle thirds is known as the \"bend\" or \"break\" in the clavicle, and serves as an important palpable landmark. (See",
"    <a class=\"local\" href=\"#H58349363\">",
"     'Subclavian vein cannulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The subclavian vein is the direct continuation of the axillary vein beginning at the lateral border of the first rib (",
"    <a class=\"graphic graphic_figure graphicRef74801 \" href=\"UTD.htm?41/21/42324\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62106 \" href=\"UTD.htm?1/53/1877\">",
"     picture 1",
"    </a>",
"    ). The vein arches cephalad behind the medial clavicle and then slopes caudally to join the internal jugular vein to form the brachiocephalic (innominate) vein posterior to the sternoclavicular joint. The vein is accompanied by the subclavian artery located superior and posterior to the vein, and separated from the vein by the anterior scalene muscle.",
"   </p>",
"   <p>",
"    The neck is a complex area with multiple structures traversing the thoracic outlet. Injury is avoided by knowing the location of these structures relative to the subclavian cannulation sites.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lung lies deep and inferior to the medial portion of the subclavian vein. The dome of the left lung often extends above the level of the first rib on the left, but rarely on the right.",
"     </li>",
"     <li>",
"      The phrenic nerve passes inferiorly along the anterior aspect of the anterior scalene muscle (",
"      <a class=\"graphic graphic_figure graphicRef52752 graphicRef52959 \" href=\"UTD.htm?31/44/32457\">",
"       figure 2A-B",
"      </a>",
"      ) and posterior to the origin of the brachiocephalic vein.",
"     </li>",
"     <li>",
"      The brachial plexus is superior and deep to the medial portion of the subclavian artery (",
"      <a class=\"graphic graphic_figure graphicRef59433 \" href=\"UTD.htm?17/58/18338\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The left-sided thoracic duct &nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef57280 \" href=\"UTD.htm?9/19/9525\">",
"       figure 4",
"      </a>",
"      ) and right-sided lymphatic duct course posterior to the subclavian vein and enter the vessel near the confluence of the left subclavian vein with the left internal jugular vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85550067\">",
"    <span class=\"h1\">",
"     SUBCLAVIAN SITE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right-handed operators often prefer right-sided subclavian access procedures. Right subclavian anatomy carries the theoretical advantage of lower risk of complications due to the lower pleural apex and absence of the thoracic duct. However, right-sided subclavian access is associated with higher rates of catheter malposition and vessel trauma compared with left-sided access [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/13\">",
"     13",
"    </a>",
"    ]. A left-sided access may be preferred when immediate cardiac access is needed (eg, temporary transvenous pacer placement, pulmonary artery catheter) since the guidewire and catheter are more easily directed into the superior vena cava and right heart.",
"   </p>",
"   <p>",
"    We avoid subclavian access ipsilateral to the compromised lung in patients with significant unilateral lung disease to avoid respiratory compromise in the event of a pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=see_link&amp;anchor=H86781613#H86781613\">",
"     \"Placement of jugular venous catheters\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with prior indwelling catheter placement in the subclavian veins or internal jugular veins, or a history of upper extremity deep venous thrombosis, we obtain Duplex ultrasound to assess venous patency prior to attempting subclavian access. This assessment is usually performed in the vascular laboratory setting. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H20#H20\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Duplex ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074744\">",
"    <span class=\"h1\">",
"     GENERAL PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General considerations for patient preparation, including catheter and access site selection, monitoring and sedation, measures to control infection, and consent, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H3104738#H3104738\">",
"     \"Overview of central venous access\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105074751\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclavian venous catheters and other subclavian venous devices are usually placed using a modified Seldinger technique in a series of defined steps usually using a kit that contains all the materials needed for their placement. Typical supplies are given in the table (",
"    <a class=\"graphic graphic_table graphicRef54646 \" href=\"UTD.htm?26/30/27115\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/14\">",
"     14",
"    </a>",
"    ]. For non-tunneled catheters, the steps for central venous catheterization are given in the table (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ). For tunneled catheters and other devices, the steps are similar except that a sheath is placed over the guidewire and the catheter (or other device such as pacemaker leads, filter) is placed through the sheath, which is then removed.",
"   </p>",
"   <p>",
"    Prior to the placement of subclavian venous catheters, assemble the following equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrasound machine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link&amp;anchor=H16#H16\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Ultrasound machine preparation'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sterile ultrasound transducer gel",
"     </li>",
"     <li>",
"      Central line kit with intravenous catheter (size and length based upon diameter and depth of vein)",
"     </li>",
"     <li>",
"      Sterile drapes, gloves, gown, surgical mask, and cap",
"     </li>",
"     <li>",
"      Topical antiseptic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=see_link\">",
"       \"Controversies in control measures to prevent surgical site infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Local anesthetic (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Isotonic saline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for flushing the catheter",
"     </li>",
"     <li>",
"      Transparent adhesive dressing, tape",
"     </li>",
"     <li>",
"      Intravenous tubing and connectors (eg, needleless Luer connector, three-way stopcock)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proper functioning of any fluoroscopic equipment that will be used should be verified. Fluoroscopy is rarely needed for subclavian access, but is routine when placing implanted catheters or devices (eg, pacemaker, defibrillator, pulmonary artery catheter, vena cava filter) to measure the length of the catheter needed and to image the sheath or device as it is introduced into the vein. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662980363\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For subclavian venous access, a wide skin preparation that includes the neck and chest above the nipple line allows the operator to attempt cannulation at an alternative ipsilateral target (eg, jugular), if the initial plan fails. If difficult access is anticipated, the neck and chest can be prepared bilaterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58338655\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;For subclavian venous access, the clinician should position the patient&rsquo;s bed or procedure table at a comfortable height. The position of the operator depends upon the vein cannulation technique chosen. We prefer to stand at the patient&rsquo;s shoulder for infraclavicular access. Standing at the head of the bed is an alternative for the supraclavicular technique. (See",
"    <a class=\"local\" href=\"#H662981166\">",
"     'Approaches to the subclavian vein'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unlike the jugular vein, Trendelenburg positioning does not significantly affect subclavian diameter, but Trendelenburg positioning may help prevent air embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Most patients can be safely positioned supine or in a Trendelenburg position. However, critically ill and obese patients may develop respiratory compromise in the supine position and even more so in Trendelenburg, requiring close monitoring. Successful supraclavicular subclavian cannulation has been performed in upright and prone positions under extenuating circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/19\">",
"     19",
"    </a>",
"    ]. Some patients may require anesthesia with a controlled airway for safe placement of central venous catheters and devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35482?source=see_link&amp;anchor=H708418#H708418\">",
"     \"Anesthesia for the obese patient undergoing non-cardiac surgery\", section on 'Positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various anatomic studies have shown that the relationship between the subclavian vein and clavicle change with head, arm, and shoulder positioning [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/15,16,20-22\">",
"     15,16,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shoulder elevation shifts the point of intersection of the vein with the clavicle more medially, and the length of overlap is reduced. Thus, to facilitate subclavian cannulation, we place the patient&rsquo;s arms at their sides (adducted) and use a neutral to lower shoulder positioning, which increases the area of contact between the subclavian vein and the undersurface of the clavicle providing a consistent landmark. A shoulder position 5 cm below neutral shoulder position appears to provide maximal amount of overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/21\">",
"     21",
"    </a>",
"    ]. The natural tendency for the shoulders to assume a cephalad orientation with Trendelenburg position must be countered by gentle caudal traction on the arm performed by a bedside assistant. One small clinical trial found improved cannulation using caudal arm traction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations to turn the head toward the side of the cannulation are based on anatomic studies and reduced catheter malposition in a single pediatric study, but such positioning has had no effect in trials on adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Special considerations for positioning patients for infraclavicular versus supraclavicular access include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infraclavicular subclavian access (",
"      <a class=\"graphic graphic_figure graphicRef82344 \" href=\"UTD.htm?9/4/9282\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62106 \" href=\"UTD.htm?1/53/1877\">",
"       picture 1",
"      </a>",
"      ), a small sandbag or rolled towel can be placed between the scapulae to retract the shoulders and facilitate needle insertion by reducing the deltoid prominence [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/26\">",
"       26",
"      </a>",
"      ]. The maneuver also positions the vein closer to the clavicle for a more consistent landmark [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/16,20\">",
"       16,20",
"      </a>",
"      ]. Avoid excessive retraction because this reduces the anterior-posterior dimension of the vein, flattening it [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For supraclavicular subclavian access (",
"      <a class=\"graphic graphic_figure graphicRef55896 graphicRef81595 \" href=\"UTD.htm?39/38/40552\">",
"       figure 6A-B",
"      </a>",
"      ), the lateral border of the clavicular head of the sternocleidomastoid muscle is the point of venous access. Contralateral rotation of the head away from the site of access provides unobstructed access [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58349363\">",
"    <span class=\"h1\">",
"     SUBCLAVIAN VEIN CANNULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subclavian vein is generally cannulated using one of three anatomic approaches with a large bore access needle using landmark techniques. Following cannulation, subclavian catheters are placed using an orderly sequence of steps (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85550527\">",
"    <span class=\"h2\">",
"     Needle access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ultrasound-guided subclavian venous access has been described, no significant benefit as yet has been identified for this access site, and thus, landmark techniques are used for needle placement. (See",
"    <a class=\"local\" href=\"#H662984945\">",
"     'Dynamic ultrasound guidance for subclavian access'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85550111\">",
"    <span class=\"h3\">",
"     General techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less commonly used compared with internal jugular vein cannulation, a seeker needle may, at times, be useful. Angiocatheters (catheter over a needle) are less commonly used to access the subclavian vein. The general technique for each of these is described below. Isolated arterial needle puncture is one of the most common complications of venous access, but is typically uneventful if recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/28\">",
"     28",
"    </a>",
"    ]. Confirmation that the access needle is in the vein is essential prior to dilating the subcutaneous tissue and vein. (See",
"    <a class=\"local\" href=\"#H662985353\">",
"     'Venous confirmation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is a learning curve for central venous access procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/29\">",
"     29",
"    </a>",
"    ]. Experienced operators enjoy greater success rates with fewer complications, among both experienced and inexperienced operators, an increased number of introducer needle passes correlates with increased complication rates, which are significantly higher after two to three unsuccessful passes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/2,10,30\">",
"     2,10,30",
"    </a>",
"    ]. If two attempts have been made, the needle should be completely removed and the surface landmarks reassessed, a new access site chosen, or assistance from a more experienced clinician obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/2,9,26\">",
"     2,9,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85550174\">",
"    <span class=\"h4\">",
"     Access with introducer needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;To access the subclavian vein with the 18 gauge introducer needle:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the introducer needle into the skin and apply continuous negative pressure by pulling back on the plunger of the syringe. Penetration into the vein will go unrecognized unless negative pressure is applied, but only a small amount of continuous negative pressure is needed (about 1 cc of a 10 cc syringe) during forward advancement of the needle.",
"     </li>",
"     <li>",
"      Always advance and withdraw the needle in the same vector. Lateral movement of an inserted needle can lacerate vessels and should",
"      <strong>",
"       not",
"      </strong>",
"      be done. Prior to any redirection of the needle, it should be withdrawn to the skin surface.",
"     </li>",
"     <li>",
"      Anticipate that venous backflow into the introducer needle will be sudden, and steady the position of your hand to avoid dislodgement from the vein when this occurs.",
"     </li>",
"     <li>",
"      Failure to aspirate blood during needle advancement is common. In this circumstance, withdraw the needle slowly while maintaining continuous negative pressure. Subclavian venous punctures may be recognized during needle withdrawal rather than insertion. Once access is achieved, stabilize the hub of the needle and carefully remove the syringe to avoid dislodging the introducer needle from the vessel.",
"     </li>",
"     <li>",
"      Cover the hub of the needle between manipulations and coordinate hub exposure with the patient&rsquo;s exhalation to avoid air entry during the subclavian access. Encourage the patient to hum or perform Valsalva maneuvers to augment central venous pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85550181\">",
"    <span class=\"h4\">",
"     Using a seeker needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more commonly used for internal jugular vein localization, a small caliber (21 to 22 gauge) exploratory seeker (or finder) needle, 3.5 cm in length, may help locate the subclavian vein (",
"    <a class=\"graphic graphic_picture graphicRef55560 \" href=\"UTD.htm?6/60/7105\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/9,31,32\">",
"     9,31,32",
"    </a>",
"    ]. This technique minimizes injury in the event of inadvertent arterial puncture. However, with the infraclavicular approach to the subclavian vein, the seeker needle may not be long enough to reach the vessel in some patients.",
"   </p>",
"   <p>",
"    To use a seeker needle to aid introducer needle placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As described above for large-bore needle access, insert the seeker needle while applying negative suction on the plunger of the syringe; more suction will be required (about 2 to 3 cc of a 10 cc syringe). Steady, unimpeded blood return confirms intraluminal venous placement.",
"     </li>",
"     <li>",
"      Once the needle enters the vein, withdraw the seeker needle, noting the angle and depth needed to reach the vein. Alternatively, remove the syringe leaving the seeker needle in place to anchor the vessel and provide a guide for venous access by the introducer needle. While applying negative pressure to the syringe, advance the introducer needle in the same vector, or alongside the preceding seeker needle, into the vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85550188\">",
"    <span class=\"h4\">",
"     Using an angiocatheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;An angiocatheter, which consists of an 18 gauge plastic catheter mounted on a 20 gauge needle, is not commonly used for initial subclavian venous access. An angiocatheter may be useful for a supraclavicular approach to the subclavian vein; however, with the infraclavicular approach, the angiocatheter may not be long enough to reach the vessel in some patients. The technique for using an angiocatheter to access the internal jugular or femoral vein is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=see_link&amp;anchor=H85542888#H85542888\">",
"     \"Placement of jugular venous catheters\", section on 'Using an angiocatheter'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link&amp;anchor=H85546471#H85546471\">",
"     \"Placement of femoral venous catheters\", section on 'Using an angiocatheter'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662981166\">",
"    <span class=\"h3\">",
"     Approaches to the subclavian vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subclavian vein can be approached from above or below the clavicle. The landmarks and needle placement for each of these approaches are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105075042\">",
"    <span class=\"h4\">",
"     Infraclavicular approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three insertion points are described for the infraclavicular approach to the subclavian vein. The midpoint approach is the most commonly used technique [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/3,20\">",
"     3,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the midpoint approach, the needle is inserted 2 to 3 cm inferior to the midpoint of the clavicle (approximately 1 cm lateral to the bend of the clavicle) and directed just posterior to the suprasternal notch (",
"      <a class=\"graphic graphic_figure graphicRef82344 \" href=\"UTD.htm?9/4/9282\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73933 \" href=\"UTD.htm?25/19/25905\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A lateral needle insertion (lateral to the midclavicular line) takes advantage of the thin anterior convexity of the clavicle to facilitate a level coronal approach, which may improve safety if the vessel can be reached by the cannulating needle [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/20,21,33\">",
"       20,21,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The medial insertion point is along the inner third of the clavicle. The needle is directed cephalad toward the suprasternal notch to penetrate the vessel at the broad confluence of the great veins. The downside of this method is that medial positioning requires a steep approach beneath the thick medial clavicle and passage through intervening soft tissue including the costoclavicular ligament.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the needle has penetrated the skin, the clavicle may be initially contacted. Take care not to push the needle into the periosteum, as bone plug can occlude the lumen of the needle. The needle should be gently &ldquo;walked&rdquo; deeper to reach the underside of the clavicle. The needle should remain parallel to the clavicle (in the coronal plane) to allow it to pass cleanly beneath the bone and minimize the risk of pleural puncture. As the needle passes beneath the junction of the middle and medial thirds of clavicle, it should enter the vein. If the first needle pass is unsuccessful, orient the needle more cephalad on subsequent attempts.",
"   </p>",
"   <p>",
"    An observational study at a large trauma center evaluated the most common errors during the placement of infraclavicular subclavian venous access [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/34\">",
"     34",
"    </a>",
"    ]. The most frequently observed errors during videotaped assessment of venous cannulation in 86 patients included improper or inadequate identification of anatomic landmarks, improper needle insertion site, too shallow a needle trajectory, and insertion of the needle through the periosteum of the clavicle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58342409\">",
"    <span class=\"h4\">",
"     Supraclavicular approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supraclavicular approach aims to puncture the subclavian vein near its junction with the internal jugular vein. The insertion of the clavicular head of the sternocleidomastoid is the access point for the supraclavicular approach to the subclavian vein (",
"    <a class=\"graphic graphic_figure graphicRef55896 \" href=\"UTD.htm?13/57/14226\">",
"     figure 6A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81595 \" href=\"UTD.htm?24/15/24821\">",
"     figure 6B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The subclavian vein is 1 to 1.5 cm deep to the skin and easily reached using a seeker needle. The needle should be inserted 1 cm posterior to the sternocleidomastoid and 1 cm cephalad to the clavicle. The needle is depressed 10 to 15 degrees below the coronal plane and oriented to bisect the angle between the clavicle and the sternocleidomastoid (",
"    <a class=\"graphic graphic_picture graphicRef53255 \" href=\"UTD.htm?32/42/33441\">",
"     picture 4",
"    </a>",
"    ). The needle is advanced toward the venous confluence behind the medial clavicle along a trajectory aimed just inferior to the contralateral nipple.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527627896\">",
"    <span class=\"h4\">",
"     Axillary approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound-guided subclavian vein access using an axillary approach is an alternative, but uncommonly used approach technique [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662984945\">",
"    <span class=\"h3\">",
"     Dynamic ultrasound guidance for subclavian access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although commonly used and recommended for internal jugular and femoral venous access sites, Duplex guidance for subclavian vein cannulation has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], but has not been found to be as useful primarily because of poor visualization of the vein due to acoustic shadowing from the overlying clavicle. The principles of ultrasound in guiding venous access are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link&amp;anchor=H1232393399#H1232393399\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Subclavian vein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662985353\">",
"    <span class=\"h2\">",
"     Venous confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intraluminal position of the needle can be confirmed by observation of the needle entering the vein with ultrasound-guided access coupled with a steady flow of dark blood into the syringe. Bright red and high-pressure pulsatile bleeding are important but imperfect clues to arterial puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/38\">",
"     38",
"    </a>",
"    ], which can occur, although less frequently, with ultrasound-guided access. Moreover, the absence of these signs is not perfectly reliable for excluding inadvertent arterial puncture. Dark, nonpulsatile backflow of blood may be seen with arterial puncture in the face of oxygen desaturation, hypotension, or needle malposition. If there is any doubt, the needle&rsquo;s location can be confirmed by pressure transduction. As an alternative, a blood gas can be drawn from the accessed venous site and compared with an arterial sample; however, blood gas analysis is more time consuming.",
"   </p>",
"   <p>",
"    To transduce the blood pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attach the needle directly to the pressure tubing system",
"     </li>",
"     <li>",
"      Alternatively, replace the needle over a guidewire with a 6 cm, 18-gauge single-lumen transduction catheter (without any intervening dilation). Connect the transduction catheter to a pressure line and transducer and evaluate the pressure and waveform tracings on the monitor. Typical venous waveforms should be seen (",
"      <a class=\"graphic graphic_figure graphicRef58343 \" href=\"UTD.htm?35/53/36701\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If a pressure transduction system is not available, attach a short length of saline-filled intravenous tubing to the needle and extended it vertically to measure the pressure, which should be &lt;10 cm in height, and should demonstrate respiratory variation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Steady, unimpeded blood return confirms intraluminal placement. The hub of the needle should be stabilized, and the syringe carefully removed to avoid dislodgement from the vessel. The needle hub should be covered between manipulations to avoid the entry of air. The patients can be encouraged to hum or perform Valsalva maneuvers to augment central venous pressure, and hub exposure can be coordinated with spontaneous exhalation to avoid aspiration of air.",
"   </p>",
"   <p>",
"    If the subclavian artery is inadvertently punctured, the needle can be withdrawn and pressure applied over the site for 5 to 10 minutes. Elevating the ipsilateral arm overhead may help to compress the vein. Subclavian access can be reattempted, but is often unsuccessful under this circumstance. If subclavian catheterization is confirmed, the catheter should be left in place and vascular consultation obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662981554\">",
"    <span class=\"h1\">",
"     CATHETER PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most catheters and other central venous devices are placed using the Seldinger method, which refers to the use of a guidewire placed into a vessel to provide a conduit for intravascular device placement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/14\">",
"     14",
"    </a>",
"    ]. Seldinger first described the guidewire technique for arterial cannulation in 1953 and it was subsequently adopted for venous access procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85551502\">",
"    <span class=\"h2\">",
"     Guidewire handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the subclavian vein has been successfully accessed, a guidewire should be advanced through the needle or angiocatheter. Multiple types of wires are available to assist with venous access procedures. The most commonly used wire for initial subclavian venous access is a flexible J-tip guidewire, favored because it negotiates curvatures and minimizes vessel trauma during passage (",
"    <a class=\"graphic graphic_picture graphicRef82419 \" href=\"UTD.htm?39/24/40320\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The subclavian approach (particularly from the right side) has the highest rate of catheter malposition compared with other access sites (jugular, femoral), which is due to errant positioning of the guidewire [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/1\">",
"     1",
"    </a>",
"    ]. Head position alters the relationship of the subclavian vein and may affect guidewire placement. (See",
"    <a class=\"local\" href=\"#H58338655\">",
"     'Positioning'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Orientation of the needle bevel caudally for infraclavicular access and medially for supraclavicular access will facilitate guidewire passage from the subclavian vein into the superior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/27\">",
"     27",
"    </a>",
"    ]. Similarly, passage of a J-tip guidewire with the J-tip directed caudally improves correct placement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/39\">",
"     39",
"    </a>",
"    ]. This maneuver may be attempted if other steps to correctly position the guidewire fail.",
"   </p>",
"   <p>",
"    Complaints of facial pain following guidewire placement often indicate passage into the internal jugular vein. Manual occlusion of the ipsilateral jugular vein during guidewire placement may decrease malposition into it [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidewire should always pass smoothly and easily thorough the needle, dilator, or catheter without resistance. Methods to address resistance to guidewire advancement or withdrawal are discussed below.",
"   </p>",
"   <p>",
"    To place the guidewire:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the tapered plastic introducer to straighten the distal J-tip (",
"      <a class=\"graphic graphic_picture graphicRef72306 \" href=\"UTD.htm?42/22/43360\">",
"       picture 6",
"      </a>",
"      ). The orientation of the bevel tip of the introducer needle and the J-tip of the wire can help facilitate the direction of wire placement.",
"     </li>",
"     <li>",
"      Maintain the residual length of guidewire (50 cm standard length) under constant manual control to maintain sterility and avoid its loss off the operating field.",
"     </li>",
"     <li>",
"      Advance the guidewire only as far as needed to allow passage of the catheter over the wire. Guidewires (and catheters) rarely require positioning more than 18 cm deep [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/5,41\">",
"       5,41",
"      </a>",
"      ]. The atriocaval junction averages 18 cm for right subclavian access, and 21 cm from the left subclavian [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/41\">",
"       41",
"      </a>",
"      ]. These average values vary depending upon stature. In an Asian study, average distances were slightly shorter at 14 cm for the right subclavian vein and 17 cm for the left subclavian vein [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/42\">",
"       42",
"      </a>",
"      ]. Advancing the guidewire deeper risks intracardiac or inferior vena cava (IVC) wire placement with the potential for cardiac arrhythmia, perforation, and snaring of other intravascular devices [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Never forcefully advance the guidewire, as this can kink and permanently deform the wire and risk vessel injury. The guidewire should always pass smoothly and easily thorough the needle, dilator, or catheter without resistance. Resistance to guidewire passage can be due to needle dislodgement, compression of the guidewire against the vessel wall, or anatomic obstruction. Rotating the needle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      guidewire to reorient the bevel or J-tip may relieve impingement of the guidewire on the posterior vessel wall.",
"     </li>",
"     <li>",
"      If resistance persists, remove the guidewire and aspirate blood to confirm intraluminal needle position. Reducing the angle of the needle against the skin may facilitate guidewire passage. Once the guidewire is positioned, hold it firmly in place, and remove the needle.",
"     </li>",
"     <li>",
"      Resistance during guidewire withdrawal can be managed by simultaneous removal of the needle and indwelling wire. Continued resistance may indicate entrapment and warrants diagnostic radiography to evaluate the wire appearance and position [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/44\">",
"       44",
"      </a>",
"      ]. Withdrawing a kinked guidewire through the needle can shear off the wire, allowing it to embolize [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86790514\">",
"    <span class=\"h2\">",
"     Tract dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheters are substantially larger caliber than the needle and guidewire used for venous access. Dilation of the subcutaneous tissue tract is required for catheter insertion and is accomplished by threading a single stiff tapered dilator or series of dilators over the wire to expand the subcutaneous tissue and vein. The skin and fascia catheter tract should be dilated carefully with gentle pressure. Only the soft tissue and vein wall need to be dilated. Overzealous efforts and guidewire kinking (especially with stiff dilators) risk traumatic vein injury.",
"   </p>",
"   <p>",
"    Many indwelling tunneled subclavian catheters are placed through a peel-away sheath. To place these devices, a dilator-sheath combination is placed over the wire after the tract has been dilated. The dilator is removed, and the catheter is placed through the sheath. Once the catheter is in place, the sheath is peeled away from the catheter and discarded. &nbsp;",
"   </p>",
"   <p>",
"    The dilator-sheath combination for large-bore tunneled catheters is stiff, and placement is facilitated with fluoroscopy, which allows imaging of the tip of the dilator and sheath, ensuring that it is placed no further into the vein than is necessary. (See",
"    <a class=\"local\" href=\"#H105074751\">",
"     'Equipment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To place the dilator:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the guidewire is in place, making a controlled 3 mm stab incision (#11 blade) in the skin at the guidewire entry site will prevent the dilator from catching.",
"     </li>",
"     <li>",
"      Thread the stiff tapered dilator over the wire, making certain the guidewire does not advance, and is not pulled out at the skin exit site. The guidewire and dilator should",
"      <strong>",
"       never",
"      </strong>",
"      be advanced as a single unit, to avoid venous injury. The wire should serve as an immobile monorail over which the dilator (or catheter) is passed. Lateral retraction of the skin may be needed to smooth the skin to avoid kinking the wire.",
"     </li>",
"     <li>",
"      Hold the wire just above the dilator hub, grasp the dilator just above its tip and push it over the guidewire with a firm corkscrew motion (",
"      <a class=\"graphic graphic_picture graphicRef77656 \" href=\"UTD.htm?35/50/36640\">",
"       picture 7",
"      </a>",
"      ). Mild resistance is normal. Excessive resistance may represent an inadequate skin incision, a malpositioned guidewire, or guidewire or dilator deformation. Kinking of the guidewire against the dilator is associated with vessel trauma and puncture [",
"      <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As described above with needle placement, the opening of the dilator (or",
"      <span class=\"nowrap\">",
"       dilator/sheath",
"      </span>",
"      combination) should be covered, and the patient encouraged to Valsalva to prevent entry of air.",
"     </li>",
"     <li>",
"      Advance the dilator only to the anticipated depth of the subclavian vein,",
"      <strong>",
"       not",
"      </strong>",
"      the entire length of the dilator. For the subclavian site, the dilator need only be advanced 3 to 5 cm into the vein depending upon the thickness of the patient&rsquo;s neck.",
"     </li>",
"     <li>",
"      Withdraw the dilator while maintaining the guidewire position within the vessel. Apply direct pressure to the exit site to maintain hemostasis prior to catheter insertion.",
"     </li>",
"     <li>",
"      Steady traction on the wire during soft-tissue dilatation helps prevent wire kinking. Rotating the dilator during advancement often facilitates tract dilatation (round dilators only). If resistance is met, it may be related to a kink in the wire which can be remedied by advancing the wire deeper or withdrawing the kink into the dilator. Overzealous efforts and guidewire kinking (especially with stiff dilators) risk traumatic vein injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662982053\">",
"    <span class=\"h2\">",
"     Positioning the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the subcutaneous tissues and vein have been dilated, the catheter is placed over the wire and positioned (",
"    <a class=\"graphic graphic_picture graphicRef70002 \" href=\"UTD.htm?27/56/28559\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To place and position the catheter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thread the guidewire back through the end-hole of the catheter until it emerges from the distal port and advance the catheter over the wire into the vessel (",
"      <a class=\"graphic graphic_picture graphicRef51314 \" href=\"UTD.htm?33/50/34593\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Resistance to catheter advancement can be overcome by simultaneously advancing the catheter and wire together, but only for a short distance otherwise subclavian vein laceration can result. Withdrawal of the catheter and redilation of the tract is preferred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ideal insertion distance varies by patient size and anatomic site. To minimize intracardiac placement, do not insert catheters more than 20 cm from any upper body access site [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/5,41\">",
"     5,41",
"    </a>",
"    ]. Initial insertion depth for most adults should be 16 cm for right-sided subclavian catheters and 20 cm for left-sided subclavian vein catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/9\">",
"     9",
"    </a>",
"    ]. Height-based formulas to determine insertion depth exist, but there are no well-controlled studies supporting their use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advancing the catheter too deep has been associated with devastating complications, including cardiac tamponade and central vein perforation. Rare case reports implicate intracardiac catheter tip placement as a possible cause of cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to right-sided catheters, catheters inserted from the left negotiate the angulation of the brachiocephalic vein to enter the superior vena cava. For large bore catheters used for hemodialysis or oncology, advancement under fluoroscopic guidance helps minimize the risk of central venous laceration. The risk of complications is related to the angle of catheter impingement on the superior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/9\">",
"     9",
"    </a>",
"    ]. From the left, catheters positioned above the pericardial reflection often abut the weak lateral wall of the superior vena cava and risk erosion and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. As such, left-sided catheters should be inserted to an appropriate length to lie parallel in the long axis of the superior vena cava. This typically requires catheter tip placement in the upper right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. It is also important to realize that catheter tips are not fixed and migrate 2 to 3 cm with head and arm movement and change in body position [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662982310\">",
"    <span class=\"h2\">",
"     Catheter flushing and fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the catheter is in place, the proper function of the catheter should be confirmed by aspirating blood and subsequently flushing each port with saline (",
"    <a class=\"graphic graphic_picture graphicRef56646 \" href=\"UTD.htm?9/12/9409\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/9,59\">",
"     9,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The catheter can be secured into place by suturing (2-0 or 3-0 nylon or silk) it to the skin (",
"    <a class=\"graphic graphic_picture graphicRef58552 \" href=\"UTD.htm?21/30/21984\">",
"     picture 11",
"    </a>",
"    ). If more than 2 cm of catheter remain exposed, it can be sutured to the skin or to a separate catheter anchor that is often included in the catheter kit. A transparent dressing should be placed over the catheter exit site to protect it from contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662982527\">",
"    <span class=\"h1\">",
"     CONFIRMATION OF SUBCLAVIAN CATHETER POSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of subclavian catheter tip location can use one or more of the following methods: chest radiography, fluoroscopy, and transesophageal echocardiography (typically intraoperative setting) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. Chest radiography and fluoroscopy are the most commonly used methods. In general, catheters function well with the tip situated in any major vein. However, suboptimal tip position may be related to delayed complications.",
"   </p>",
"   <p>",
"    Following subclavian access, the position and course of the catheter and tip should be confirmed prior to its use. When using fluoroscopy for placement, a routine chest radiograph is unnecessary unless clinical suspicion of",
"    <span class=\"nowrap\">",
"     pneumothorax/hemothorax",
"    </span>",
"    is high. If fluoroscopy has not been used, we obtain a postprocedure chest radiograph in non-life-threatening situations. If immediate catheter use is needed, venous positioning (but not tip position) can be confirmed with transduction of the central venous pressure, display of the central venous waveform or with ultrasound. Bedside ultrasound is under investigation as an alternative modality to confirm catheter placement and detect pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/67\">",
"     67",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The optimal catheter tip position is controversial, and controlled studies are lacking. The distal tip of jugular catheters should lie in the lower superior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. To minimize the likelihood of cardiac complications, some guidelines recommend catheter tip position outside the right atrium and above the pericardial reflection. The right superior heart border on chest radiography is not a reliable determinant of right atrial position [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/68\">",
"     68",
"    </a>",
"    ]. The carina and right tracheobronchial angle represent reliable landmarks for the pericardial reflection and right-sided catheters should generally be positioned above this point [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malposition is common with subclavian access and is often related to an initially misplaced guidewire [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/1\">",
"     1",
"    </a>",
"    ]. If a catheter is malpositioned within the venous system, it can be used for fluid administration under emergency circumstances, but should be re-positioned as soon as feasible. In contrast, inadvertent placement of a catheter into the subclavian artery mandates surgical consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/27/1466/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a subclavian catheter tip is positioned too deeply, it can be repositioned at the bedside using sterile technique. Remove the sutures, withdraw the catheter, and re-suture the catheter into place.",
"     </li>",
"     <li>",
"      If a catheter is not in far enough or is misplaced into the contralateral subclavian or internal jugular vein, it will need to be replaced over a guidewire under sterile conditions. The portion of a catheter left out of the body is unsterile and should never be advanced into the patient, not even if it is under a sterile dressing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105076021\">",
"    <span class=\"h1\">",
"     CATHETER MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of central catheters is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Site care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Catheter care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86790556\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications related to subclavian venous access are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86790563\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central catheters provide dependable intravenous access and enable hemodynamic monitoring and blood sampling. The subclavian veins are reliable access points for temporary and permanent cannulation, and device introduction. Several anatomical approaches to the subclavian vein are described, and the method should be individualized to the patient&rsquo;s clinical circumstances. (See",
"      <a class=\"local\" href=\"#H86790388\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For subclavian access, the patient is placed supine or in Trendelenburg position with the arms placed to the side (adducted) with a neutral to lower shoulder positioning. The natural tendency for the shoulders to assume a cephalad orientation during Trendelenburg tilt should be countered by gentle caudal arm traction performed by a bedside assistant. (See",
"      <a class=\"local\" href=\"#H58338655\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subclavian artery puncture during vein localization is not uncommon and can be managed by withdrawing the needle and applying pressure over the site for 5 to 10 minutes. Elevation of the ipsilateral arm overhead may help to compress the vein. Venous access can be re-attempted, but may not be successful. If arterial catheterization is confirmed, the catheter should be left in place and a vascular consult obtained. (See",
"      <a class=\"local\" href=\"#H662985353\">",
"       'Venous confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following placement of central catheters placed using a subclavian approach, we obtain a postprocedure chest radiograph to confirm correct catheter position and assess for complications, including pneumothorax. The distal tip of subclavian catheters should lie in the lower superior vena cava. (See",
"      <a class=\"local\" href=\"#H662982527\">",
"       'Confirmation of subclavian catheter position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a subclavian catheter is placed too deeply, it can be withdrawn at the bedside using sterile techniques. If the catheter is not placed deeply enough or is malpositioned, the catheter should be replaced over a guidewire under sterile conditions. The portion of a catheter left out of the body is unsterile and should never be advanced into the patient. (See",
"      <a class=\"local\" href=\"#H662982527\">",
"       'Confirmation of subclavian catheter position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A postprocedure chest radiograph is typically performed to confirm catheter position and exclude pneumothorax. The distal tip of subclavian catheters should lie in the lower superior vena cava. (See",
"      <a class=\"local\" href=\"#H662982527\">",
"       'Confirmation of subclavian catheter position'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/1\">",
"      Ruesch S, Walder B, Tram&egrave;r MR. Complications of central venous catheters: internal jugular versus subclavian access--a systematic review. Crit Care Med 2002; 30:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/2\">",
"      McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/3\">",
"      AUBANIAC R. [Subclavian intravenous injection; advantages and technic]. Presse Med 1952; 60:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/4\">",
"      Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy--a prospective audit. Intensive Care Med 1999; 25:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/5\">",
"      McGee WT, Moriarty KP. Accurate placement of central venous catheters using a 16-cm catheter. J Intensive Care Med 1996; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/6\">",
"      Doerfler ME, Kaufman B, Goldenberg AS. Central venous catheter placement in patients with disorders of hemostasis. Chest 1996; 110:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/7\">",
"      Mumtaz H, Williams V, Hauer-Jensen M, et al. Central venous catheter placement in patients with disorders of hemostasis. Am J Surg 2000; 180:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/8\">",
"      Foster PF, Moore LR, Sankary HN, et al. Central venous catheterization in patients with coagulopathy. Arch Surg 1992; 127:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/9\">",
"      Polderman KH, Girbes AJ. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med 2002; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/10\">",
"      Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994; 331:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/11\">",
"      Timsit JF. Central venous access in intensive care unit patients: is the subclavian vein the royal route? Intensive Care Med 2002; 28:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/12\">",
"      Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant 1991; 6:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/13\">",
"      The clinical anatomy of several invasive procedures. American Association of Clinical Anatomists, Educational Affairs Committee. Clin Anat 1999; 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/14\">",
"      SELDINGER SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol 1953; 39:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/15\">",
"      Land RE. Anatomic relationships of the right subclavian vein. A radiologic study pertinent to percutaneous subclavian venous catheterization. Arch Surg 1971; 102:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/16\">",
"      Fortune JB, Feustel P. Effect of patient position on size and location of the subclavian vein for percutaneous puncture. Arch Surg 2003; 138:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/17\">",
"      Ely EW, Hite RD, Baker AM, et al. Venous air embolism from central venous catheterization: a need for increased physician awareness. Crit Care Med 1999; 27:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/18\">",
"      Mirski MA, Lele AV, Fitzsimmons L, Toung TJ. Diagnosis and treatment of vascular air embolism. Anesthesiology 2007; 106:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/19\">",
"      Sunder-Plassmann G, Locker GJ, Muhm M, et al. Central venous catheterization in a patient in the prone position. Crit Care Med 1997; 25:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/20\">",
"      Tan BK, Hong SW, Huang MH, Lee ST. Anatomic basis of safe percutaneous subclavian venous catheterization. J Trauma 2000; 48:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/21\">",
"      Kitagawa N, Oda M, Totoki T, et al. Proper shoulder position for subclavian venipuncture: a prospective randomized clinical trial and anatomical perspectives using multislice computed tomography. Anesthesiology 2004; 101:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/22\">",
"      Land RE. The relationship of the left subclavian vein to the clavicle: practical considerations pertinent to the percutaneous catheterization of the subclavian vein. J Thorac Cardiovasc Surg 1972; 63:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/23\">",
"      Jesseph JM, Conces DJ Jr, Augustyn GT. Patient positioning for subclavian vein catheterization. Arch Surg 1987; 122:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/24\">",
"      Jung CW, Bahk JH, Kim MW, et al. Head position for facilitating the superior vena caval placement of catheters during right subclavian approach in children. Crit Care Med 2002; 30:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/25\">",
"      Sanchez R, Halck S, Walther-Larsen S, Heslet L. Misplacement of subclavian venous catheters: importance of head position and choice of puncture site. Br J Anaesth 1990; 64:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/26\">",
"      Boyd R, Saxe A, Phillips E. Effect of patient position upon success in placing central venous catheters. Am J Surg 1996; 172:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/27\">",
"      Nevarre DR, Domingo OH. Supraclavicular approach to subclavian catheterization: review of the literature and results of 178 attempts by the same operator. J Trauma 1997; 42:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/28\">",
"      Guilbert MC, Elkouri S, Bracco D, et al. Arterial trauma during central venous catheter insertion: Case series, review and proposed algorithm. J Vasc Surg 2008; 48:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/29\">",
"      Sznajder JI, Zveibil FR, Bitterman H, et al. Central vein catheterization. Failure and complication rates by three percutaneous approaches. Arch Intern Med 1986; 146:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/30\">",
"      Lefrant JY, Muller L, De La Coussaye JE, et al. Risk factors of failure and immediate complication of subclavian vein catheterization in critically ill patients. Intensive Care Med 2002; 28:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/31\">",
"      Tripathi M, Tripathi M. Subclavian vein cannulation: an approach with definite landmarks. Ann Thorac Surg 1996; 61:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/32\">",
"      Albuquerque J&uacute;nior FC, Vasconcelos PR. Technical aspects of central venous catheterization. Curr Opin Clin Nutr Metab Care 1998; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/33\">",
"      Tofield JJ. A safer technique of percutaneous catheterization of the subclavian vein. Surg Gynecol Obstet 1969; 128:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/34\">",
"      Kilbourne MJ, Bochicchio GV, Scalea T, Xiao Y. Avoiding common technical errors in subclavian central venous catheter placement. J Am Coll Surg 2009; 208:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/35\">",
"      Abboud PA, Kendall JL. Ultrasound guidance for vascular access. Emerg Med Clin North Am 2004; 22:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/36\">",
"      Fragou M, Gravvanis A, Dimitriou V, et al. Real-time ultrasound-guided subclavian vein cannulation versus the landmark method in critical care patients: a prospective randomized study. Crit Care Med 2011; 39:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/37\">",
"      O'Leary R, Ahmed SM, McLure H, et al. Ultrasound-guided infraclavicular axillary vein cannulation: a useful alternative to the internal jugular vein. Br J Anaesth 2012; 109:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/38\">",
"      Ezaru CS, Mangione MP, Oravitz TM, et al. Eliminating arterial injury during central venous catheterization using manometry. Anesth Analg 2009; 109:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/39\">",
"      Tripathi M, Dubey PK, Ambesh SP. Direction of the J-tip of the guidewire, in seldinger technique, is a significant factor in misplacement of subclavian vein catheter: a randomized, controlled study. Anesth Analg 2005; 100:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/40\">",
"      Ambesh SP, Dubey PK, Matreja P, et al. Manual occlusion of the internal jugular vein during subclavian vein catheterization: a maneuver to prevent misplacement of catheter into internal jugular vein. Anesthesiology 2002; 97:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/41\">",
"      Andrews RT, Bova DA, Venbrux AC. How much guidewire is too much? Direct measurement of the distance from subclavian and internal jugular vein access sites to the superior vena cava-atrial junction during central venous catheter placement. Crit Care Med 2000; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/42\">",
"      Kim WY, Lee CW, Sohn CH, et al. Optimal insertion depth of central venous catheters--is a formula required? A prospective cohort study. Injury 2012; 43:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/43\">",
"      Stuart RK, Shikora SA, Akerman P, et al. Incidence of arrhythmia with central venous catheter insertion and exchange. JPEN J Parenter Enteral Nutr 1990; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/44\">",
"      Wang HE, Sweeney TA. Subclavian central venous catheterization complicated by guidewire looping and entrapment. J Emerg Med 1999; 17:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/45\">",
"      Propp DA, Cline D, Hennenfent BR. Catheter embolism. J Emerg Med 1988; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/46\">",
"      Robinson JF, Robinson WA, Cohn A, et al. Perforation of the great vessels during central venous line placement. Arch Intern Med 1995; 155:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/47\">",
"      Czepizak CA, O'Callaghan JM, Venus B. Evaluation of formulas for optimal positioning of central venous catheters. Chest 1995; 107:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/48\">",
"      Peres PW. Positioning central venous catheters--a prospective survey. Anaesth Intensive Care 1990; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/49\">",
"      Booth SA, Norton B, Mulvey DA. Central venous catheterization and fatal cardiac tamponade. Br J Anaesth 2001; 87:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/50\">",
"      Collier PE, Blocker SH, Graff DM, Doyle P. Cardiac tamponade from central venous catheters. Am J Surg 1998; 176:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/51\">",
"      Tocino IM, Watanabe A. Impending catheter perforation of superior vena cava: radiographic recognition. AJR Am J Roentgenol 1986; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/52\">",
"      Dailey RH. Late vascular perforations by CVP catheter tips. J Emerg Med 1988; 6:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/53\">",
"      Duntley P, Siever J, Korwes ML, et al. Vascular erosion by central venous catheters. Clinical features and outcome. Chest 1992; 101:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/54\">",
"      Mukau L, Talamini MA, Sitzmann JV. Risk factors for central venous catheter-related vascular erosions. JPEN J Parenter Enteral Nutr 1991; 15:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/55\">",
"      Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth 2000; 85:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/56\">",
"      Vesely TM. Central venous catheter tip position: a continuing controversy. J Vasc Interv Radiol 2003; 14:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/57\">",
"      Stonelake PA, Bodenham AR. The carina as a radiological landmark for central venous catheter tip position. Br J Anaesth 2006; 96:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/58\">",
"      Kowalski CM, Kaufman JA, Rivitz SM, et al. Migration of central venous catheters: implications for initial catheter tip positioning. J Vasc Interv Radiol 1997; 8:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/59\">",
"      Chalkiadis GA, Goucke CR. Depth of central venous catheter insertion in adults: an audit and assessment of a technique to improve tip position. Anaesth Intensive Care 1998; 26:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/60\">",
"      Gillman LM, Blaivas M, Lord J, et al. Ultrasound confirmation of guidewire position may eliminate accidental arterial dilatation during central venous cannulation. Scand J Trauma Resusc Emerg Med 2010; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     Gu X, Paulsen W, Tisnado J, He Y, Li Z, Nixon JV: Malposition of a central venous catheter in the right main pulmonary artery detected by transesophageal echocardiography. J Am Soc Echocardiogr 2009; 22:1420",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/62\">",
"      Lucey B, Varghese JC, Haslam P, Lee MJ. Routine chest radiographs after central line insertion: mandatory postprocedural evaluation or unnecessary waste of resources? Cardiovasc Intervent Radiol 1999; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/63\">",
"      Gebhard RE, Szmuk P, Pivalizza EG, et al. The accuracy of electrocardiogram-controlled central line placement. Anesth Analg 2007; 104:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/64\">",
"      Abood GJ, Davis KA, Esposito TJ, et al. Comparison of routine chest radiograph versus clinician judgment to determine adequate central line placement in critically ill patients. J Trauma 2007; 63:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/65\">",
"      Wirsing M, Schummer C, Neumann R, et al. Is traditional reading of the bedside chest radiograph appropriate to detect intraatrial central venous catheter position? Chest 2008; 134:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/66\">",
"      Francis KR, Picard DL, Fajardo MA, Pizzi WF. Avoiding complications and decreasing costs of central venous catheter placement utilizing electrocardiographic guidance. Surg Gynecol Obstet 1992; 175:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/67\">",
"      Vezzani A, Brusasco C, Palermo S, et al. Ultrasound localization of central vein catheter and detection of postprocedural pneumothorax: an alternative to chest radiography. Crit Care Med 2010; 38:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/68\">",
"      Aslamy Z, Dewald CL, Heffner JE. MRI of central venous anatomy: implications for central venous catheter insertion. Chest 1998; 114:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/69\">",
"      Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth 2000; 85:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/27/1466/abstract/70\">",
"      Albrecht K, Nave H, Breitmeier D, et al. Applied anatomy of the superior vena cava-the carina as a landmark to guide central venous catheter placement. Br J Anaesth 2004; 92:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15673 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-543A21084C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1466=[""].join("\n");
var outline_f1_27_1466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86790563\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86790388\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86790395\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86790402\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86790409\">",
"      SUBCLAVIAN VEIN ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85550067\">",
"      SUBCLAVIAN SITE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105074744\">",
"      GENERAL PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105074751\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662980363\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58338655\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58349363\">",
"      SUBCLAVIAN VEIN CANNULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85550527\">",
"      Needle access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85550111\">",
"      - General techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85550174\">",
"      Access with introducer needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85550181\">",
"      Using a seeker needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85550188\">",
"      Using an angiocatheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H662981166\">",
"      - Approaches to the subclavian vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H105075042\">",
"      Infraclavicular approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H58342409\">",
"      Supraclavicular approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H527627896\">",
"      Axillary approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H662984945\">",
"      - Dynamic ultrasound guidance for subclavian access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662985353\">",
"      Venous confirmation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662981554\">",
"      CATHETER PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85551502\">",
"      Guidewire handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86790514\">",
"      Tract dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662982053\">",
"      Positioning the catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662982310\">",
"      Catheter flushing and fixation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662982527\">",
"      CONFIRMATION OF SUBCLAVIAN CATHETER POSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105076021\">",
"      CATHETER MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86790556\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86790563\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15673|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/21/42324\" title=\"figure 1\">",
"      Anatomy SC IJ central line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/21/16725\" title=\"figure 2A\">",
"      Left phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17061\" title=\"figure 2B\">",
"      Right phrenic nerve course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/58/18338\" title=\"figure 3\">",
"      Anatomy of the thoracic outlet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/19/9525\" title=\"figure 4\">",
"      Anatomy of thoracic duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/4/9282\" title=\"figure 5\">",
"      SC central line infra mid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/57/14226\" title=\"figure 6A\">",
"      SC central line supra",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/15/24821\" title=\"figure 6B\">",
"      Central line SC supra anat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/53/36701\" title=\"figure 7\">",
"      Right atrial pressure tracing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15673|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/53/1877\" title=\"picture 1\">",
"      Central line SC infra anat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/60/7105\" title=\"picture 2\">",
"      Central line IJ finder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/19/25905\" title=\"picture 3\">",
"      Central line SC mid needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/42/33441\" title=\"picture 4\">",
"      Central L SC supra needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/24/40320\" title=\"picture 5\">",
"      Central line J wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/22/43360\" title=\"picture 6\">",
"      Central line wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/50/36640\" title=\"picture 7\">",
"      Central line dilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/56/28559\" title=\"picture 8\">",
"      Central line catheter wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/50/34593\" title=\"picture 9\">",
"      Central line catheter insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/12/9409\" title=\"picture 10\">",
"      Aspiration following central venous catheter placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/30/21984\" title=\"picture 11\">",
"      Central line suture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/53/1885\" title=\"table 1\">",
"      Advantages and disadvantages of central vein approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27115\" title=\"table 2\">",
"      Central line equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/26/44459\" title=\"table 3\">",
"      Technique of central venous catheterization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35482?source=related_link\">",
"      Anesthesia for the obese patient undergoing non-cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=related_link\">",
"      Placement of femoral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=related_link\">",
"      Placement of jugular venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_27_1467="Masquerade syndromes uveitis";
var content_f1_27_1467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Masquerade syndromes that mimic uveitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Giant retinal tears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocular melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmentary dispersion syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinitis pigmentosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinoblastoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1467=[""].join("\n");
var outline_f1_27_1467=null;
var title_f1_27_1468="Criteria multiple primary LC";
var content_f1_27_1468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for diagnosis of multiple primary lung cancers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Martini, N, Melamed, MR. Multiple primary cancers. J Thorac Cardiovasc Surg 1975; 70:606",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Definition of synchronous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Concurrent, separate, malignant lung epithelial neoplasms with different histology, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumors of similar histology arising in different locations (segments,",
"lobes, lung): (1) origin from carcinoma in situ, (2) no carcinoma in",
"lymphatics common to both, (3) no extrapulmonary metastases at the time",
"of diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Definition of metachronous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histology different",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histology same if: (1) free interval between cancers at least 2 years, or (2) origin from",
"carcinoma in situ, or (3) second cancer in different lobe or lung, and",
"(a) no carcinoma in lymphatics common to both, (b) no extrapulmonary",
"metastases at time of diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antakli, T, Schaefer, RF, Rutherford, JE, et al. Second primary lung cancer. Ann Thorac Surg 1995; 59:863",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Different histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Same histology with two or more of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Anatomically distinct",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Associated premalignant lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. No systemic metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. No mediastinal spread",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Different DNA ploidy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1468=[""].join("\n");
var outline_f1_27_1468=null;
var title_f1_27_1469="Urogynecologic reconstructive materials terminology";
var content_f1_27_1469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Urogynecological Association/International Continence Society terminology and classification of complications related to insertion of prostheses and grafts in female pelvic floor surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Terms used",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Prosthesis",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        A fabricated substitute to assist a damaged body part or to augment or stabilize a hypoplastic structure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mesh",
"       </td>",
"       <td>",
"        A (prosthetic) network fabric or structure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Implant",
"       </td>",
"       <td>",
"        A surgically inserted or embedded prosthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tape (sling)",
"       </td>",
"       <td>",
"        A flat strip of synthetic material",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Graft",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Any tissue or organ for transplantation; refers to biological materials inserted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autologous grafts",
"       </td>",
"       <td>",
"        From the woman's own tissues (eg, dura mater, rectus sheath or fascia lata)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allografts",
"       </td>",
"       <td>",
"        From post-mortem tissue banks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xenografts",
"       </td>",
"       <td>",
"        From other species (eg, modified porcine dermis, porcine small intestine, bovine pericardium)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Complication",
"        </strong>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        A morbid process or event that occurs during the course of a surgery that is not an essential part of that surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contraction",
"       </td>",
"       <td>",
"        Shrinkage or reduction in size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prominence",
"       </td>",
"       <td>",
"        Parts that protrude beyond the surface (eg, due to wrinkling or folding with no epithelial separation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Separation",
"       </td>",
"       <td>",
"        Physically disconnected (eg, vaginal epithelium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exposure",
"       </td>",
"       <td>",
"        A condition of displaying, revealing, exhibiting or making accessible (eg, vaginal mesh visualized through separated vaginal epithelium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extrusion",
"       </td>",
"       <td>",
"        Passage gradually out of a body structure or tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Compromise",
"       </td>",
"       <td>",
"        Bring into danger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perforation",
"       </td>",
"       <td>",
"        Abnormal opening in a hollow organ or viscus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dehiscence",
"       </td>",
"       <td>",
"        A bursting open or gaping along natural or sutured line",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Haylen BT, Freeman RM, Swift SE, et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Int Urogynecol J 2011; 22:3, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1469=[""].join("\n");
var outline_f1_27_1469=null;
var title_f1_27_1470="Molecular test encephalitis";
var content_f1_27_1470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular tests for encephalitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Availability*",
"       </td>",
"       <td class=\"subtitle1\">",
"        When inclusion of NAAT is indicated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preferred testing method(s)",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coxiella burnetti (Q fever)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT, serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Listeria spp",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Culture +/- NAAT, serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium tuberculosis&Delta;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Potentially",
"       </td>",
"       <td>",
"        AFB stain, culture, histologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fastidious (Mycoplasma spp, Bartonella spp)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        Serology, NAAT including alternative sites where appropriate (eg, respiratory)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenoviruses",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Testing of alternative sites (eg, respiratory) +/- CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arboviruses",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"       <td>",
"        Yes&nbsp;",
"       </td>",
"       <td>",
"        When clinically suspected&nbsp;",
"       </td>",
"       <td>",
"        Serology and NAAT, preferably quantitative&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroviruses",
"       </td>",
"       <td>",
"        Widespread",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human herpesvirus 6 (HHV-6)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT, preferably quantitative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus (HSV)",
"       </td>",
"       <td>",
"        Widespread",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Testing of alternative sites (eg, respiratory) +/- CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphocytic choriomeningitis virus (LCM)",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mumps",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        History, culture, serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rabies&loz;",
"       </td>",
"       <td>",
"        Limited (CDC)",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        Combination of serology, biopsy, NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus (VZV)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        When clinically suspected",
"       </td>",
"       <td>",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West Nile virus&sect;",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Rarely (unless immunodeficient)",
"       </td>",
"       <td>",
"        Serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptococcus",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Antigen detection, culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other fungi",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Culture, serology, histologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Rickettsia&yen;&nbsp;",
"       </td>",
"       <td>",
"        Limited&nbsp;",
"       </td>",
"       <td>",
"        Occasionally&nbsp;",
"       </td>",
"       <td>",
"        Serology&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Spirochetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Borrelia burgdorferi (the cause of Lyme disease)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Serology,&nbsp;NAAT&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;Treponema pallidum (syphilis)",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        When clinically suspected&nbsp;",
"       </td>",
"       <td>",
"        Serology, CSF VDRL&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microsporidia",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Rarely",
"       </td>",
"       <td>",
"        Serology, stains, histologic exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other parasites (Baylisascaris spp, Balamuthia mandrillaris)&nbsp;",
"       </td>",
"       <td>",
"        Limited&nbsp;",
"       </td>",
"       <td>",
"        Rarely (eg, CSF eosinophilia)&nbsp;",
"       </td>",
"       <td>",
"        Histologic exam, serology +/- NAAT&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPV: positive predictive value; CDC: Centers for Disease Control and Prevention; NAAT: nucleic acid amplification testing; CSF: cerebrospinal fluid; AFB: acid fast bacilli.",
"     <br>",
"      * Widespread: readily available; Yes: consistently available, but not yet common; Limited: one or two specialized laboratories (eg, Centers for Disease Control and Prevention (CDC) or research groups).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Test on CSF except where noted.",
"       <br>",
"        &Delta; Limited experience, presumably poor sensitivity, high PPV.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         In conjunction with other modalities.",
"         <br>",
"          &sect; Virus is usually cleared from blood and CSF prior to symptom onset.",
"          <br>",
"           &yen; Limited experience from CSF.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1470=[""].join("\n");
var outline_f1_27_1470=null;
var title_f1_27_1471="Syphilitic uveitis";
var content_f1_27_1471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Syphilitic uveitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundus photograph from a patient with syphilitic uveitis. The retinal vessel has areas adjacent to it of focal inflammation, and the retina has become depigmented such that choroidal vessels beneath the retina can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_27_1471=[""].join("\n");
var outline_f1_27_1471=null;
